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Die Rolle der MAP Kinase p38α in akuten und chronischen Entzündungsreaktionen 
Jan Heinrichsdorff, Institute für Genetik, Universität zu Köln, Deutschland 
Die Leber spielt eine wichtige Rolle für das Gleichgewicht im Körper da sie wichtige 
Stoffwechselfunktionen ausübt. Neben synthetischen und exkretorischen Funktionen hat die 
Leber auch wichtige immunologische Aufgaben. Diese Funktionen werden vor allem von 
Zytokinen gesteuert. Während der nuclear factor-kB (NF-κB) Signalweg vor allem anti 
apoptotische Funktionen hat, und Zellen vor TNF induziertem Tod schützt, hat der c-Jun amino-
terminal kinase (JNK) Signalweg proapoptotische Funktionen. 
Die Kinase p38α ist ein Mitglied Familie der MAP Kinasen und wird durch diverse entzündliche 
Reaktionen aktiviert. Darüber hinaus wurde gezeigt, dass p38α eine Funktion in der 
Zellproliferation, in der Differenzierung von Zellen und beim programmierten Zelltod hat. Ziel 
dieser Promotionsarbeit war es, die Rolle von p38α in akuten und chronisch entzündlichen 
Reaktionen in der Leber zu untersuchen. Hierzu wurden leberspezifische p38α knockout Mäuse 
generiert und in einem Model LPS/TNF induzierter akuter Leberentzündung sowie einem Model 
von Diät induzierter Fettleibigkeit untersucht.  
Nach LPS Injektion führt die leberspezifische Deletion von p38α zu einer verstärkten Aktivierung 
der MAP Kinase JNK. Die verstärkte Aktivierung von JNK führt nicht zu einer erhöhten 
Sensitivität für LPS/TNF induzierte Leberschädigung. Im Gegensatz dazu, führt eine LPS 
Injektion in Mäusen mit einer leberspezifischen Deletion für p38α und die IκB kinase 2 (IKK2) zu 
akuten Leberversagen. Folglich führt eine partielle Inhibierung von NF-κB in Kombination mit 
p38α Defizienz zu akuter Leberschädigung. Die Ergebnisse zeigen eine neue Rolle von p38α das 
zusammen mit IKK2 LPS/TNF induzierte Leberschädigungen verhindert.  
 
Darüber hinaus führt die Deletion von p38α in der Leber zu erhöhter Insulinresistenz in einem 
Model von Diät induzierter Fettleibigkeit und Insulinresistenz. p38α defiziente Lebern und primäre 
Hepatozyten zeigen eine Einschränkung von Insulin vermittelten Signalen. Dagegen hat der p38α 
Knockout keinen Einfluss auf Quantität und Qualität von Leberlipiden. Auch eine erhöhte 
Expression von entzündlichen Zytokinen in der Leber wurde nicht detektiert. Eine erhöhte 
Aktivität von JNK und seinen Aktivatoren MKK4, TAK1 und ASK1 scheint für die eingeschränkte 
Ansprechbarkeit von p38α defizienten Zellen durch Insulin verantwortlich zu sein. 
Folglich scheint die Kinase p38α in der Leber eine wichtige Funktion bei der Regulation der 
Glukosehomeostase zu haben, da  sie eine Reihe von Kinasen reguliert die negativen Einfluss 
auf Insulin vermittelte Signale nehmen können. 
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The role of liver p38α MAP kinase during acute and chronic inflammatory states  
Jan Heinrichsdorff, Institute for Genetics, University of Cologne, Germany 
The liver plays an important role in body homeostasis due to its inflammatory, metabolic and 
synthetic functions. Cytokines control these functions by activating various intracellular signaling 
pathways. Activation of the nuclear factor-kB (NF-κB) pathway protects cells from TNF-induced 
apoptosis by inducing the expression of anti-apoptotic proteins, while sustained c-Jun amino-
terminal kinase (JNK) is important for TNF-induced killing of NF-κB-deficient cells.  
The p38 mitogen-activated protein kinase (p38) is a member of the MAP kinase family and is 
activated by various inflammatory stimuli. p38 was shown to regulate cellular responses to stress 
and is implicated in cell proliferation, differentiation and apoptosis. To investigate the function of 
p38α in the liver during acute and chronic inflammatory conditions, mice with a liver parenchymal 
cell specific ablation of p38α were generated. Two models of inflammation, a model of acute 
LPS/TNF induced liver toxicity and a model of diet induced obesity were applied. 
Upon challenge with bacterial lipopolysaccharide (LPS), liver parenchymal cell specific ablation of 
p38α results in excessive activation of JNK. Despite increased JNK activity, p38α deficient 
hepatocytes are not sensitized to LPS/TNF induced apoptosis, suggesting that JNK activation is 
not sufficient to mediate TNF-induced liver damage. By contrast, LPS injection caused liver failure 
in mice lacking both p38α and IκB kinase 2 (IKK2) in liver parenchymal cells through decreased 
level of the anti apoptotic molecule c-FLIP (L). Thus, hyperactivation of JNK combined with partial 
inhibition of NF- κB sensitizes the liver to cytokine-induced damage, revealing a new function of 
p38α in collaborating with IKK2 to protect the liver from LPS/TNF-induced failure.  
 
Furthermore, deletion of the p38α MAPK in liver parenchymal cells results in increased insulin 
resistance in obese mice. p38α deficient livers and isolated primary hepatocytes show increased 
insulin resistance while liver lipids remain unaffected ruling out a possible accumulation of lipid 
intermediates that could negatively regulate insulin signaling. Moreover, an elevated expression 
of inflammatory cytokines was not detected. Increased activation of kinases including JNK, 
MKK4, TAK1 and ASK1 is likely to be responsible for the increased insulin resistance in p38α 
deficient hepatocytes. Thus, in obese mice, liver p38α might have an important function 
regulating glucose homeostasis by controlling the activity of kinases that might be responsible for 
the negative regulation of insulin signaling. 
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„… because the liver is a source of many diseases, and it is a noble organ that serves many 
other organs, almost all of them: so it suffers, it is not a small suffering, but a great manifold 
one“ 
Paracelsus (1494-1541) 
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1. Introduction 
 
1.1 The liver 
 
The liver is the largest solid organ present in vertebrates. It has a wide range of functions 
keeping the body in homeostasis. The liver plays a major role in glucose and glycogen 
metabolism, lipid and lipoprotein synthesis, hormone production, decomposition of red blood 
cells and detoxification. It produces bile, an alkaline compound which aids in digestion and 
detoxification, via the emulsification of lipids. The liver also performs and regulates a wide 
variety of high-volume biochemical reactions requiring highly specialized tissues, including 
the synthesis and breakdown of small and complex molecules, many of which are necessary 
for normal vital functions. It is absolutely essential for survival; there is currently no way to 
compensate for the absence of liver function as opposed to  - for example – blood dialysis in 
kidney dysfunction. 
 
With respect to its anatomical location the liver has a unique position in the body. Situated 
below the diaphragm in the thoracic region of the abdomen it allows continuous blood flow 
from the gastrointestinal tract through the sinusoids. A human liver consists of 2 lobes, 
comprising 1/50 of the body weight of an adult. In contrast, a mouse liver consists of 4 lobes 
(Martins, Theruvath et al. 2008). 
 
In terms of its cellular composition, the liver is a heterogeneous organ. Circulating blood 
cells, from the innate or adaptive immune system and a variety of intrahepatic cell 
populations such as parenchymal liver cells (hepatocytes 60-65% and biliary epithelial cells 
3,5% off all liver cells), the sinusoidal cell compartment including endothelial cells (15-20%), 
liver-resident macrophage (Kupffer cells 8-12%), lymphocyte [mainly natural killer T (NKT) 
cells] populations and hepatic stellate cells (3-8%) steer the different hepatic functions 
(Racanelli and Rehermann 2006).  
 
The function of the diverse cell populations in the liver is orchestered by cytokines, which are 
key mediators within the complex interplay of intrahepatic immune cells and hepatocytes. 
Cytokines can activate effector functions of immune cells, as well as intracellular signaling 
pathways within the hepatocytes, acting as key players controlling cellular homeostasis. 
Serving as autocrine, paracrine or endocrine messengers, cytokines are essential mediators 
that influence various liver functions including inflammatory and metabolic responses 
(Luedde, Liedtke et al. 2002). 
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In the liver, Kupffer cells and liver-infiltrating monocyte-derived macrophages are primary 
sources of cytokines, such as tumor-necrosis factor alpha (TNF) and Interleukin-6 (IL-6). 
Especially TNF seems to play an outstanding role controlling liver homeostasis and is 
therefore involved in important functions in liver physiology and pathology. TNF activates 
specific intracellular pathways in hepatocytes that influence cell fate in different manners, 
through the activation of proapoptotic signals via caspase or Mitogen-activated protein 
kinase (MAPK) cascades, but also survival pathways, like the nuclear factor-kappaB (NF-κB) 
pathway. Recent experiments with genetically modified mice demonstrated important and 
partly opposing functions induced by TNF receptor (TNFR) signaling. While on the one hand 
TNF is able to promote cell survival and liver regeneration, on the other hand it can act as a 
death inducing cytokine. Therefore, the dissection of hepatocyte responses to TNF in 
homeostasis and injury could potentially identify novel targets for the treatment of many 
acute and chronic liver diseases. 
 
1.2 Tumor Necrosis Factor   
 
TNF was initially described 30 years ago as an endotoxin induced serum factor that induces 
death in BALB/c sarcomas (Carswell, Old et al. 1975). Independently, TNF was described as 
a factor mediating differentiation of hematopoetic cells into the monocyte/macrophage linage 
(Takeda, Iwamoto et al. 1986) and as a hormone produced by activated macrophages, 
responsible for hypertriglyceridemia and wasting of adipose tissue in cancer patients and 
patients suffering from infections (Beutler, Greenwald et al. 1985; Fried and Zechner 1989). It 
was shown to control a diverse range of physiological functions, many of which are related to 
the immune response and inflammation. TNF has been shown to play an important role in 
leukocyte migration, tissue resorption, and fever response (Beutler and Cerami 1989).  
 
TNF binds to two plasma membrane receptors, TNF-receptor I (TNFR I) and TNF-receptor II 
(TNFR II) (Brockhaus, Schoenfeld et al. 1990; Dembic, Loetscher et al. 1990; Schall, Lewis 
et al. 1990). Whereas TNFR I is the receptor for soluble TNF, TNFR II mediates effects 
through the membrane bound TNF precursor and seems mostly restricted to T cells (Zheng, 
Fisher et al. 1995; Kim and Teh 2001; Depuydt, van Loo et al. 2005). The majority of the 
biological effects induced by TNF seem to be mediated by TNFR I through the activation of 
NF-κB and the initiation of MAPK cascades as well as cell death inducing caspase cascades. 
The diversity of the different pathways that are activated by TNFR I is mediated through 
different adaptor proteins recruited to the cytoplasmic part of the receptor. The cytoplasmic 
part of the TNFR I contains a Death Domain (DD) that is shared by a number of receptors 
promoting cell death (Tartaglia, Rothe et al. 1993). The Death Domain creates a binding 
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scaffold for downstream mediators of TNFR I signaling such as TNFR I Associated Death 
Domain protein (TRADD), Fas Associated Death Domain protein (FADD), Receptor 
Interacting Protein 1 (RIP1), TNF Receptor Associated Factor 2 (TRAF2) and other factors 
(Hsu, Xiong et al. 1995; Hsu, Huang et al. 1996; Hsu, Shu et al. 1996). According to the 
current model, two complexes are built upon receptor activation. Complex I leads to the 
activation of NF-κB, the MAP kinase pathways c-Jun N-terminal kinase (JNK) and p38. TNF-
mediaded activation of NF-κB is initiated by the recruitment of the adaptor molecules 
TRADD, TRAF2, and Rip to the cytoplasmic part of TNFR I. Once this complex is formed, 
TRAF2 and RIP1 cooperate to recruit the TGFβ-activated kinase 1 (TAK1). TRAF2 contains 
ubiquitin ligase activity and leads to the addition of Lys-63 ubiquitin chains to RIP1. These 
ubiquitin chains are recognized by TAB2/3 which both mediate the recruitment of TAK1 
(Chen and Goeddel 2002; Chen 2005). Activated TAK1 phosphorylates the critical residues 
on IKK2 and leads to the activation of NF-κB signaling (Wang, Deng et al. 2001; Sato, Sanjo 
et al. 2005; Shim, Xiao et al. 2005). TAK1 is a member of the MAP3K family. Therefore, 
recruitment of TAK1 to the TNFR I does not only cause TNF induced activation of NF-κB, it 
also causes activation of the MAP kinases JNK and p38. The mechanisms leading to 
temporal and spatial separation of MAPK and NF-κB signaling downstream of TNFR I are 
currently under investigation (Matsuzawa, Tseng et al. 2008). In contrast, Complex II, which 
forms after dissociation of the membrane proximal complex I from TNFR I, induces 
hepatocyte apoptosis by recruiting the adaptor molecules FADD and TRADD. FADD 
contains a death effector domain by which it can recruit procaspase 8. The clustering of 
procaspase 8 in the DISC complex leads to its autoactivation. Active caspase 8 is then able 
to proteolytically activate other effector caspases initiating apoptosis (Micheau and Tschopp 
2003). In cells that lack substantial NF-κB activity, formation of complex II results in caspase-
8 activation and apoptotic cell death (Muppidi, Tschopp et al. 2004) However, if NF-κB has 
been activated during complex I formation, it prevents caspase 8 activation by the DISC 
complex through induction of antiapoptotic genes like the cellular FLICE-inhibitory protein (c-
FLIP), an adaptor protein with a pseudocaspase domain that specifically inhibits caspase-8 
(Thome and Tschopp 2001). Thus, NF-κB may negatively regulate TNF induced apoptosis 
through regulation of  c-FLIP levels and its activation serves as a checkpoint that determines 
whether the DISC complex will signal cell death or not (Muppidi, Tschopp et al. 2004). 
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1.3 TNF induced signaling in hepatocytes 
 
In the healthy liver, cytokine production is absent or very low. During liver inflammation cells 
are exposed to increased levels of TNF. TNF induction is known as one of the earliest events 
of hepatic inflammation triggering a cascade of other cytokines that cooperate in recruiting 
inflammatory cells, killing of hepatocytes and initiating wound healing responses (Bradham, 
Plumpe et al. 1998). Depending on the cellular context, exposure of hepatocytes to TNF 
induces signals that mediate cell death or survival pathways, which allow hepatocytes to 
survive and recover from tissue damage (Akerman, Cote et al. 1992; Yamada, Kirillova et al. 
1997; Yin, Wheeler et al. 1999; Rudiger and Clavien 2002). Moreover, in addition to its role in 
triggering life and death decisions in hepatocytes, TNF has also been shown to affect 
important metabolic functions in the liver. TNF expression is upregulated in the fat of obese 
rodents and humans and is elevated in the serum of patients with type 2 diabetes. 
Additionally, it has been shown to cause insulin resistance in hepatocytes in vivo and in vitro 
(Uysal, Wiesbrock et al. 1997; Hotamisligil 1999) 
 
As a result of this complex interplay between different signaling cascades activated 
downstream of the TNFR I, there are different levels of regulation determining the biological 
outcome of the TNF induced signaling. Various conflicting signaling pathways lead to a wide 
spectrum of TNF induced responses ranging from cell survival to cell death. These signals 
also influence cell metabolism, gene expression, differentiation, adhesion and mortality 
(Shaulian and Karin 2002). Especially NF-κB and MAPK mediated responses to TNF 
signaling in the liver were a subject of intense investigation in the last decade. 
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Graph 1: TNFR I signaling TNFR1 activation leads to formation of complex I at the cytoplasmic tail of the 
receptor resulting in JNK1 and IKK activation. Complex I dissociates from the receptor.  Complex II, which 
includes FADD, is formed. If c-FLIP (L) levels are high (high NF-κB, low JNK activation), caspase-8 recruitment to 
FADD and its subsequent activation are inhibited and the cells survive. If c-FLIP (L) levels are low (low NF-κB, 
high JNK), caspase-8 is recruited to FADD and activated, leading to apoptotic cell death. Image taken from 
Chang, L et al. 2006 Cell. 
 
1.3.1 NF-κB signaling in the liver 
 
NF-κB was identified about 20 years ago as a transcription factor that binds to the intronic 
enhancer of the kappa light chain gene in B cells (Sen and Baltimore 1986; Sen and 
Baltimore 1986). The family of NF-κB transcription factors consists of p50 and its precursor 
p105, p52 and its precursor p100, RelA (p65), c-Rel and RelB all of which share a Rel 
homology domain responsible for homo and heterodimerisation as well as for sequence 
specific DNA binding. RelA, c-Rel and RelB also contain a C-terminal transcription activation 
domain, whereas p50 and p52 do not and rely on interactions with other partners to positively 
regulate transcription (Hayden and Ghosh 2008). In resting cells, NF-κB transcription factors 
are normally kept in an inactive state in the cytoplasm through the binding to inhibitors of κB 
proteins IκBs (IκBα, IκBβ, IκBγ) and the precursor proteins p100 and p105.  
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Many different stimuli can activate NF-κB transcription factors and induce their nuclear 
accumulation (Ghosh and Karin 2002; Bonizzi and Karin 2004) which is controlled by the IκB 
kinases (IKKs).  
The major and most well known pathway to activate NF-κB is the so called canonical NF-κB 
pathway. Activation is controlled by the IKK complex consisting of IKK1, IKK2 and the 
regulatory subunit nuclear factor-kappa B essential modulator (NEMO). Upon cell stimulation 
the IKK complex phosphorylates the IκB proteins that keep the NF-κB transcription factors in 
the cytoplasm. This leads to ubiquitination and degradation of the IκB proteins. As a result 
the NF-κB transcription factors enter the nucleus and activate gene transcription. In the case 
of canonical NF-κB signaling, mainly RelA:p50 and c-Rel:p52 heterodimers translocate to the 
nucleus (Mercurio, Zhu et al. 1997; Woronicz, Gao et al. 1997; Yamaoka, Courtois et al. 
1998). 
The so called non-canonical NF-κB signaling pathway relies on activation through receptors 
that are mainly involved in developmental processes like the lymphotoxin beta receptor or B 
cell activating factor (BAFF). Here, IKK1 acts independent from IKK2 and NEMO 
(Senftleben, Cao et al. 2001; Derudder, Dejardin et al. 2003) and leads to the 
phosphorylation and proteolytic processing of p100 to p52 which leads to the nuclear 
accumulation of p52:RelB dimers (Senftleben, Cao et al. 2001). 
Healthy hepatocytes are resistant to cytotoxic effects of TNF. NF-κB signaling may give an 
essential survival stimulus that balances the effects of the cell death machinery that are 
activated by TNF. If NF-κB signaling is impaired as reported in RelA, NEMO and IKK2 
deficient mice, embryonic lethality results due to TNF induced degradation of the fetal liver 
(Beg, Sha et al. 1995; Li, Van Antwerp et al. 1999; Rudolph, Yeh et al. 2000). Additional 
deletion of TNF or TNFR I rescues the embryonic lethality of these mice (Doi, Marino et al. 
1999). This in vivo evidence showing that NF-κB prevents TNF mediated cell death is also 
supported by in vitro studies with hepatocytes which, if transfected with a dominant negative 
IκBα, are sensitive to TNF induced apoptosis (Bellas, FitzGerald et al. 1997).  
The activation of NF-κB influences the pathogenesis of several TNF-mediated hepatic 
diseases. In TNF induced liver injury, wild type mice are only sensitized to TNF induced cell 
death upon co-administration of D-Galactosamine (GalN). GalN is a hepatotoxin that blocks 
transcription specifically in hepatocytes, including the transcription of anti-apoptotic NF-κB 
target genes, and therefore sensitizes mice to TNF induced lethality (Decker and Keppler 
1974). To the same extent GalN sensitizes mice to bacterial Lipopolysaccaride (LPS) a 
strong inducer of TNF. Moreover, in liver regeneration after partial hepatectomy, TNF 
induced NF-κB plays an important role due to the induction of interleukin 6 (IL-6) (Cressman, 
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Greenbaum et al. 1996). Liver NF-κB also seems to play a role in carcinogenesis. IKK2 liver 
deficient mice develop more hepatocellular carcinomas after diethylnitrosamine (DEN) 
treatment due to a higher rate of hepatocyte apoptosis and compensatory proliferation 
(Maeda, Kamata et al. 2005). Furthermore, in mice lacking NEMO specifically in the liver, cell 
death and the spontaneous development of chronic hepatitis result in the development of 
hepatocellular carcinomas. This process is initiated by hypersensitivity of NEMO deficient 
hepatocytes to oxidative stress dependent, FADD mediated apoptosis, triggering 
compensatory cell proliferation, inflammation and activation of progenitor cells (Luedde, 
Beraza et al. 2007). Similar to the DEN model, hepatocyte specific deletion of NEMO 
highlights the essential anti-apoptotic role of NF-κB avoiding cell death followed by 
compensatory proliferation and cancer. NF-κB also processes inflammatory responses since 
its activation does not only lead to the expression of anti-apoptotic mediators but also to the 
expression of inflammatory cytokines. Indeed, deletion of IKK2 in the liver seems to prevent 
liver insulin resistance due to a lower expression of inflammatory cytokines that affect insulin 
signaling (Arkan, Hevener et al. 2005) while liver specific hyperactivation of IKK2 has the 
opposite effect (Cai, Yuan et al. 2005). 
 
1.3.2 MAP kinase cascades  
 
Besides NF-κB signaling, ligand binding to TNFR I also activates Mitogen-activated protein 
kinases (MAPKs), in particular c-Jun n-terminal kinases (JNK) and p38.  
MAPKs are evolutionary conserved serine-threonine kinases that connect cell surface 
receptors to critical regulatory targets within the cells. Mammals express at least four 
distinctly related groups of MAPKs, (1) extracellular signal related kinases (ERK) 1/2, (2) Jun 
n-terminal kinases (JNK) 1/2/3, (3) p38 proteins α, β, γ, δ and (4) ERK 5.   
 
MAPKs are activated by phosphorylation cascades. These cascades consist of a set of three 
evolutionarily conserved, sequentially acting kinases: (1) a MAPK, (2) a MAPK kinase 
(MAP2K), and (3) an MAPK kinase kinase (MAP3K). MAP3Ks, are Ser/Thr kinases that are 
activated via phosphorylation or through interaction with small GTP proteins of the Ras/Rho 
family in response to a wide range of extracellular stimuli. MAP3K activation leads to 
phosphorylation and activation of a downstream MAP2K. MAP2Ks are dual specificity 
kinases that can phosphorylate MAPK on both threonine and tyrosine on a conserved Thr-x-
Tyr motif to activate them. The Thr-x-Tyr phosphorylation motif is localized in an activation 
loop near the ATP- and substrate-binding sites. Once activated, MAPKs phosphorylate their 
target substrates on serine or threonine residues only if the amino acid residues are followed 
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by proline. A wide variety of MAPK substrates exists, among them transcription factors, other 
kinases (MAPK activated kinases or MKs) or proteins like cytoskeletal proteins. Each of 
these cascades is named after the subgroup of its MAPK component ERK1/2, JNK, p38 or 
ERK 5. In mammals 20 genes encoding for MAP3Ks have been reported, followed by 7 
MAP2Ks and 11 MAPKs genes (Uhlik, Abell et al. 2004). Different extracellular signals can 
produce stimulus- and tissue-specific responses by activating one or more MAPK pathways. 
In addition, MAPK-activated protein kinases (MKs), the downstream targets of MAPKs, 
further contribute to additional specificity, diversity and amplification in the MAPK cascades.   
 
 
 
 
 
 
 
 
 
 
 
Graph 2: MAPK signaling. (A) MAPK signaling pathways mediate intracellular signaling that can be initiated by a 
variety of extracellular or intracellular stimuli. Initially, MAP3Ks, which are activated by MAP4Ks or GTPases, 
mediate phosphorylation and activation of MAP2Ks, which in turn phosphorylate and activate MAPKs. Activated 
MAPKs phosphorylate various substrate proteins including transcription factors, resulting in regulation of a variety 
of cellular activities including cell proliferation, differentiation, migration, inflammatory responses, and death. (B) 
The p38 and JNK pathways are activated by a MAP3K such as ASK1, MEKK1, or MLK3 as well as a MAP2K 
such as MKK3 or MKK6 for the p38 pathway and MKK4 or MKK7 for the JNK pathway. Pictures taken from 
Kyung, E et al. 2010 Biochimica et Biophysica Acta. 
One of the most explored functions of MAPK signaling modules is the regulation of gene 
expression in response to extracellular stimuli (Treisman 1996). MAPKs function inside the 
nucleus and target transcription factors that are bound to DNA. It has also been reported that 
MAPKs regulate gene expression through post-transcriptional mechanisms involving 
cytoplasmic targets. (Chen, Gherzi et al. 2000).  
           A                          B 
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The biological outcomes of MAPK signaling include a wide range of functions including cell 
proliferation, differentiation, survival, death and transformation. These functions are 
particularly important in an organ like the liver which has a high proliferative and regenerative 
capacity and always balances between cell survival and cell death. In contrast to NF-κB, 
MAPK signaling is considered to be rather diverse with pro-apoptotic but also anti-apoptotic 
functions. 
Two members of the MAPK family, JNK and the p38 signaling pathway, can be activated by 
TNF in response to cellular stress such as genotoxic, osmotic, hypoxic or oxidative stress.  
 
1.3.3 JNK signaling in the liver 
 
The family of JNK protein kinases is encoded by 3 different genes. The JNK 1 and JNK 2 
genes are expressed ubiquitously while JNK 3 expression has a limited pattern and is 
restricted to the brain, heart and testis (Gupta, Barrett et al. 1996).  
JNK is activated by the dual specificity MAP2Ks MKK4 and MKK7, which are activated by 
their upstream MAP3Ks through phosphorylation on serine or threonine residues in the 
activation loop. A wide range of MAP3Ks have neen described, which most likely act in a cell 
type and stimulus-specific manner (Davis 1995). The first and most potent JNK-activating 
MAP3K identified was MEKK1 (Gerwins, Blank et al. 1997). However, numerous other 
MAP3Ks, which can activate JNK were identified, including: MEKK2 and MEKK3 (Blank, 
Gerwins et al. 1996), MEKK4 (Gerwins, Blank et al. 1997), Mixed Lineage kinases 2 and 3 
(MLK2 and MLK3) (Hirai, Izawa et al. 1996; Tibbles, Ing et al. 1996), Dual leucine zipper-
bearing kinase (DLK) (Fan, Merritt et al. 1996), Tumor progression locus-2 (Tpl-2) 
(Salmeron, Ahmad et al. 1996), TGF-β-activated kinase (TAK1) (Yamaguchi, Shirakabe et al. 
1995), Apoptosis Signal Regulating Kinases 1 and 2 (ASK1 and ASK2) (Ichijo, Nishida et al. 
1997), and Thousand and one amino acid kinases 1 and 2 (Tao1 and Tao2) (Chen, 
Hutchison et al. 1999). The large number of MAP3Ks that can activate the JNK cascade 
have made the identification of the individual family member responsible for JNK activation 
by distinct stimuli extremely difficult. 
The organization of MAPK cascades as distinct signaling modules allows their highly 
coordinated and specific activation response to extracellular stimuli (Davis 2000). Thus, the 
presence of a large number of JNK-activating MAP3Ks in mammals may provide the benefit 
of improved signal specificity to diverse types of physiological and stress stimuli. 
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Another level of regulation adding specificity to JNK signaling is the scaffolding of proteins, 
which includes the JNK Interacting Proteins (JIP) like scaffolds (Davis 1999) and the MKKs. 
(Xia, Wu et al. 1998; Morrison and Davis 2003). Besides the purpose of specificity, 
scaffolding might also serve the purpose of amplifying a signal.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 3: JNK Scaffolding JIP-1 can act as a scaffold assembling  specific components of JNK activation 
including the upstream kinase HPK-1, the MAP3K MLK1, the MA2K MKK7 and the MAPK JNK into a signaling 
module. Picture taken from Chang L et al. 2001 Nature. 
 
JNK proteins phosphorylate a wide range of transcription factors including c-Jun which is 
phosphorylated at Ser 63 and 74 leading to increased transcriptional activity (Pulverer, 
Kyriakis et al. 1991) and AP-1 proteins like JunB, JunD and Atf2 (Auer, Contessa et al. 1998; 
Ip and Davis 1998). JNK appears to be important for AP-1 target gene activation caused by 
stress and cytokines but is not required for AP-1 transcriptional activation by other stimuli 
(Yang, Tournier et al. 1997).  
 
In recent years, JNK isoforms have been recognized as critical regulators of various aspects 
of mammalian physiology, including: cell proliferation, cell survival, cell death, DNA repair 
and metabolism. Upon TNF signaling, the duration and magnitude of JNK activation seems 
to be determined by the balance between activating MKKs. Only a modest and transient JNK 
activation is required for TNF-induced cell proliferation, whereas an intense and prolonged 
JNK activation mediates cell death (Kamata, Honda et al. 2005) highlighting the critical 
balance of TNF induced JNK activation for the outcome of the biological response. 
                           A 
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After partial hepatectomy, which induces TNF, JNK is activated and is instrumental for liver 
regeneration (Schwabe, Bradham et al. 2003). On the other hand, in livers and hepatocytes 
unable to activate NF-κB, JNK activity controls TNF-induced death through the proteasomal 
processing of c-FLIP (L) (Chang, Kamata et al. 2006). Moreover, JNK plays a role in DEN 
induced hepatocarcinogenesis. In hepatocytes, NF-κB activation promotes sustained JNK 
activation in cells exposed to TNF, whose expression is induced by DEN. JNK activity is 
required for normal hepatocyte proliferation and liver regeneration. Mice lacking JNK1 were 
much less susceptible to DEN-induced hepatocarcinogenesis. The decreased tumorigenesis 
in JNK1-/- mice was shown to correlate with decreased expression of cyclin D and vascular 
endothelial growth factor, diminished cell proliferation, and reduced tumor neovascularization 
(Sakurai, Maeda et al. 2006). JNK also seems to be involved in the negative regulation of 
insulin signaling. It has been demonstrated in vitro that JNKs can phosphorylate the insulin 
receptor substrate (IRS1) on serine 307, which correlates with reduced Insulin receptor 
mediated IRS1 tyrosine phosphorylation leading to a decreased transduction of the insulin 
stimulus (Aguirre, Uchida et al. 2000). Moreover, JNK isoforms undergo activation in 
response to pro inflammatory cytokines, such as TNF, which is elevated during obesity 
(Kallunki, Su et al. 1994). Indeed, it was observed that consumption of high fat diet (HFD) or 
genetic obesity results in JNK activation (Hirosumi, Tuncman et al. 2002) and that JNK1-/- 
mice are protected from diet induced obesity and insulin resistance, even though in this 
model the tissue specific contributions of JNK1 to this phenotype were not addressed. 
Furthermore, treatment of obese mice with a cell permeable peptide inhibitor of JNK was 
found to result in improved insulin sensitivity (Bogoyevitch, Boehm et al. 2004). It is also of 
interest that mutations in the Jip1 gene have been found in patients with a genetic form of 
type II diabetes (Waeber, Delplanque et al. 2000). This suggests that a JIP1-organized JNK1 
cascade plays an important role in the regulation of insulin signaling.  
In contrast to JNK, which has been studied in various different models in the liver,  the 
functions of p38, another MAPK activated by TNF signaling, are far less understood. 
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1.3.4 p38 MAPK 
  
Human p38 was originally discovered as the molecular target of the pyridinyl imidazole class 
of compounds that were known to inhibit biosynthesis of inflammatory cytokines such as 
interleukin-1 (IL-1) and TNF in lipopolysaccharide (LPS) stimulated human monocytes (Lee, 
Laydon et al. 1994). Later, the murine p38α MAPK was identified as a major phosphoprotein 
activated by LPS and inflammatory cytokines (Han, Lee et al. 1994). So far, four isoforms of 
p38 MAPK have been identified. Of these, the ubiquitously expressed p38α is the best 
characterized and perhaps the most physiologically relevant kinase involved in inflammatory 
responses. Besides p38α, p38β was identified which has >70% identity to p38α (Jiang, Chen 
et al. 1996; Kumar, McDonnell et al. 1997). Later, p38γ (also known as SAPK3 and 
MAPK12) and p38δ (also known as SAPK4 and MAPK13) (Li, Jiang et al. 1996; Mertens, 
Craxton et al. 1996) were identified. These kinases have ~60% identity to p38α and much 
less is known about their function.  
  
p38 MAPK is activated though a classical MAPK activation cascade involving a MAP3K, that 
activates a MAP2K which then activates the MAPK p38. Activation of p38 occurs by dual 
phosphorylation on Thr180 and Tyr182 by an upstream MAP2K termed MKK6. Other 
MAP2Ks, such as MKK3 have also been suggested to activate p38 MAPK. MKK6 is 
activated by several MAP3Ks, which are in turn activated by a wide variety of stimuli 
including MAP3Ks activated in response to various physical and chemical stresses, such as 
oxidative stress, UV irradiation, hypoxia, ischemia, and various cytokines, including 
interleukin-1 (IL-1) and TNF (Adams, Badger et al. 2001; Chen, Gibson et al. 2001; Kyriakis 
and Avruch 2001). 
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Graph 4: p38 MAPK pathway activators and substrates Environmental stress and/or inflammatory cytokines 
activate MAP3Ks through a variety of signaling mechanisms. Activated MAP3Ks subsequently activate MAP2Ks, 
which in turn activate MAPKs. Activated MAPKs then phosphorylate several substrates, such as transcription 
factors, other kinases and cytosolic proteins. Picture taken from Kumar et al. 2003 Nat. Rev. 
 
MEK4 (also known as MKK4 and Sek1) is a known JNK kinase that possesses some MAP2K 
activity toward p38, suggesting that MEK4 represents a site of integration for the p38 and 
JNK pathways. While MKK6 activates all p38 isoforms, MKK3 is somewhat selective, as it 
preferentially phosphorylates the p38α and p38β isoforms. 
 
The first p38α substrate identified was the MAP kinase- activated protein kinase 2 
(MAPKAPK2 or MK2) (Freshney, Rawlinson et al. 1994; Rouse, Cohen et al. 1994; 
McLaughlin, Kumar et al. 1996). MK2, along with its closely related family member MK3, 
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were both shown to activate various substrates including small heat shock protein 27 
(HSP27) (Stokoe, Engel et al. 1992), lymphocyte-specific protein 1 (LSP1) (Huang, Zhan et 
al. 1997), cAMP response element-binding protein (CREB) (Tan, Rouse et al. 1996), 
transcription factor ATF1, SRF (Heidenreich, Neininger et al. 1999), and tyrosine hydroxylase 
(Thomas, Haavik et al. 1997). MNK1 is another kinase substrate of p38 whose function is 
thought to reside in translational initiation due to the observation that MNK1 and MNK2 can 
phosphorylate eukaryotic initiation factor-4e (eIF-4E) (Waskiewicz, Flynn et al. 1997). 
Another group of substrates that are activated by p38 comprises transcription factors. Many 
transcription factors encompassing a broad range of action have been shown to be 
phosphorylated and subsequently activated by p38. Examples include activating transcription 
factor 1, 2 & 6 (ATF-1/2/6), SRF accessory protein (Sap1), CHOP (growth arrest and DNA 
damage inducible gene 153, or GADD153), p53, C/EBPβ, myocyte enhance factor 2C 
(MEF2C), MEF2A, MITF1, DDIT3, ELK1, NFAT, and high mobility group-box protein 1 
(HBP1) (Hazzalin, Cano et al. 1996; Wang and Ron 1996; Han, Jiang et al. 1997; Janknecht 
and Hunter 1997; Whitmarsh, Yang et al. 1997; Huang, Ma et al. 1999; Zhao, New et al. 
1999; Yee, Paulson et al. 2004). An important cis-element, AP-1 appears to be influenced by 
p38 through several different mechanisms. ATF-2 is known to form heterodimers with Jun 
family transcription factors thereby directly associating with the AP- 1 binding site. Another 
possible mechanism comes from the observation that a component of AP-1 is c-fos. c-fos is 
known to be SRE dependent and SRE is able to bind Ternary Complex Factor (TCF). 
Ternary Complex mFactor is comprised of Sap-1a, a protein that is phosphorylated by p38. 
Thus, p38 indirectly regulates AP-1 activity. 
 
Considering the wide range of substrates linked to p38 MAPKs, it is a natural consequence 
that this kinase should also be involved in a wide and diverse variety of functions. Indeed, 
roles for p38 MAPKs have been described in processes such as cell differentiation and 
migration, cell transformation, cell survival, inflammation, angiogenesis, myogenesis and 
others.  
 
The fact that p38-/- mice are lethal at embryonic day 10.5 has deprived researchers of an 
important genetic tool for functional studies in vivo. Four groups have reported the generation 
of these mice (Adams, Porras et al. 2000; Allen, Svensson et al. 2000; Mudgett, Ding et al. 
2000; Tamura, Sudo et al. 2000). Insufficient vascularization during placental development 
was described as a possible cause of death. Mudget et al. found that in addition to the 
placental defect, angiogenesis was also abnormal in the yolk sac and the embryo itself. 
Adams et al. reported massive reduction of the myocardium and malformation of blood 
vessels in the head region. However, this defect appears to be secondary to insufficient 
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oxygen and nutrient transfer across the placenta. Finally, fetuses surviving to relatively late 
stages of development are anemic and have a deficiency of erythropoietin (Epo) mRNA 
expression in their liver. Therefore, the studies conducted on p38 function have been 
restricted to in vitro assays and stimulus specific functions in the context of a specific organ 
like the liver could not be addressed so far. 
Among other processes, p38 seems to play a role in inflammation. Rheumatoid arthritis, 
Alzheimer’s disease and inflammatory bowel disease are all postulated to be regulated in 
part by the p38 pathway (Perregaux, Dean et al. 1995; Johnson and Bailey 2003; 
Hollenbach, Neumann et al. 2004). p38 signaling seems to play an essential role in the 
production of proinflammatory cytokines (IL-1β, TNF and IL-6) (Guan, Buckman et al. 1998). 
Moreover, p38 has a role in the expression of intracellular enzymes such as iNOS, a 
regulator of oxidation (Da Silva, Pierrat et al. 1997; Craxton, Shu et al. 1998), induction of 
VCAM-1 and other adherent proteins along with other inflammatory related molecules 
(Pietersma, Tilly et al. 1997).  
The role of p38 in apoptosis seems to be cell type and stimulus dependent. While p38 
signaling has been shown to promote cell death in some cell lines, in other cell lines p38 has 
been shown to enhance survival, cell growth, and differentiation. There is evidence that p38 
might act up and downstream of caspases in apoptosis (Ziegler-Heitbrock, Blumenstein et al. 
1992; Cardone, Salvesen et al. 1997).  
Furthermore, the participation of p38 in cell growth has been observed in yeast and 
mammals (Takenaka, Moriguchi et al. 1998). Overexpression of p38 in yeast led to 
significant attenuation of proliferation, while treatment in mammalian cells with p38α/β 
inhibitor SB203580 slowed proliferation as well. p38 has been implicated in G1 and G2/M 
phases of the cell cycle in several reports (Molnar, Theodoras et al. 1997; Wang, McGowan 
et al. 2000).  
p38α and p38β have been implicated in the differentiation of certain cell types. Differentiation 
of 3T3-L1 cells into adipocytes and PC12 cells into neurons requires p38α and/or β 
(Engelman, Lisanti et al. 1998). More recently, a cross-talk model between the p38 pathway 
and phosphatidylinositol 3-kinase (PI3 kinase)/Akt in the orchestration of myoblast 
differentiation has been proposed (Iwasa, Han et al. 2003).  
Moreover, p38 seems to have a role in tumorigenesis and sensescence. There have been 
reports that activation of MKK6 and MKK3 led to a senescent phenotype dependent upon 
p38 MAPK activity. Also, p38 MAPK activity was shown responsible for senescence in 
response to telomere shortening, H2O2 exposure, and chronic RAS oncogene signaling 
(Wang, Chen et al. 2002). 
p38 might also be involved in the energy metabolism of certain organs. Here, most studies 
are restricted to in vitro work. The few in vivo studies were carried out with p38 inhibitors. In 
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the liver, p38 might participate in the processes to increase blood glucose levels through 
reducing glycogen synthesis and increasing hepatic gluconeogenesis (Cao, Collins et al. 
2005). p38 appears to prevent fat storage by inhibiting hepatic lipogenesis and promoting 
fatty acid oxidation in the liver. Additionally, p38 may play a critical role in cholesterol 
metabolism by regulating expression of the LDLR gene and bile metabolism, but many 
functions remain controversial (Cao, Collins et al. 2005; Cao, Xiong et al. 2007).  
 
1.4        The role of p38α in acute and chronic inflammatory diseases 
 
As mentioned before, a strong link has been established between the p38α pathway and 
inflammation. Rheumatoid arthritis, Alzheimer’s disease and inflammatory bowel disease are 
all postulated to be regulated in part by the p38 signaling pathway (Johnson and Bailey 2003; 
Hollenbach, Neumann et al. 2004). Furthermore, the activation of the p38 pathway plays an 
essential role in the production of proinflammatory cytokines like IL-1β, TNF and IL-6 (Guan, 
Buckman et al. 1998). All three cytokines were reported to play important roles in liver 
homeostasis and disease. In contrast to NF-κB and JNK, the tissue specific role of liver p38α 
during various inflammatory conditions remains to be investigated in vivo. Thus, as a central 
topic of this thesis, the role of liver p38α in acute and chronic inflammatory reactions was 
investigated. In order to do this, two mouse models of inflammation were chosen. For the 
role of liver p38α in acute inflammatory reactions, a model of LPS/TNF induced acute liver 
toxicity was applied. To investigate the role of p38α in chronic low grade inflammatory 
reactions a model of diet induced obesity and insulin resistance was utilized.  
 
1.4.1        LPS/TNF induced acute liver failure 
 
The liver is the central metabolic organ in the body fulfilling important functions ranging from 
carbohydrate and lipid metabolism, to synthetic and excretory functions. Due to these central 
functions processed in the liver, diseases of this organ can lead to severe symptoms. The 
liver has an outstanding potential to regenerate and is able to compensate lack of function for 
an extended period of time. Therefore, symptoms arise very late during the course of 
disease, which makes diagnosis and therapy of liver diseases extremely difficult. Often, liver 
damage is recognized at a very late stage (Sass and Shakil 2003).  
Acute liver damage can be caused by a wide range of substances, including toxins and 
drugs like Paracetamol or Halothan. In addition, sepsis or ischemic hepatitis after surgery 
can lead to acute liver failure. The liver is able to tolerate and compensate chronic sickness 
like viral infections, parasites or metabolic disorders to a certain degree. Nevertheless, once 
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the amount of intact hepatocytes falls below a certain threshold, acute liver failure is the 
consequence.  
Two molecular mechanisms were identified to cause liver failure: (1) Necrosis. Due to 
disruption of cellular metabolism caused by various insults, acute lack of ATP and 
dysregulation of ion homeostasis lead to cell swelling and rupture of the cell membrane. As a 
result intracellular proteins, ions and metabolites leak into the surrounding tissue causing 
recruitment of immune cells and inflammatory reactions (Bauer 2002). (2) The second 
molecular mechanism that can induce liver failure is programmed cell death (Apoptosis). 
Apoptosis is an essential process during embryonic development and tissue remodeling. 
Cells die without affecting the surrounding tissue since they are phagocytozed by immune 
cells. Intracellular pathways like the caspase cascades lead to rapid apoptosis of cells 
(Neuman 2001). In the liver, apoptosis is initiated during viral infections or by inflammatory 
cytokines like TNF when necessary survival stimuli are not present. TNF seems to have an 
outstanding role in liver failure caused by ischemia/reperfusion injury (Colletti, Remick et al. 
1990), alcohol induced hepatitis (Felver, Mezey et al. 1990), chronic viral hepatitis 
(Gonzalez-Amaro, Garcia-Monzon et al. 1994) and poisoning by toxins (Leist, Gantner et al. 
1997). Elevated serum levels of TNF were shown in patients with liver failure (Muto, Nouri-
Aria et al. 1988). Patients that died from acute liver failure showed significantly higher levels 
of TNF in their serum than patients that survived (Bird, Sheron et al. 1990). The amount of 
apoptotic or necrotic hepatocytes can be directly correlated to the expression of TNF and 
underlines the outstanding role TNF has during the development of liver failure (Streetz, 
Leifeld et al. 2000). In light of the importance that TNF has in the development of acute liver 
failure it is essential to understand the molecular mechanisms that underlie this process. TNF 
is known to activate MAP kinases including p38α. In order to find new targets for medical 
intervention in cases of acute liver failure it is important to gain more knowledge about the 
molecular events that precede this severe medical condition.  
 
 
1.4.2        Chronic inflammatory states in the liver: diet induced obesity and insulin 
lllllllllllllllresistance 
 
The incidence of obesity worldwide has increased drastically during recent decades. 
Consequently, obesity and associated disorders now constitute a serious threat to the 
current and future health of the world population. The World Health Organization estimates 
that more than 1 billion adults worldwide are overweight, 300 million of who are clinically 
obese (World Health Organization, 2002 Geneva). With obesity, comes a variety of adverse 
health outcomes, such as high blood pressure, insulin resistance, and type 2 diabetes 
(Mokdad, Ford et al. 2003; Reaven 2005).  
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The metabolic disorder diabetes mellitus is characterized by chronic hyperglycemia, caused 
by an absolute or relative insulin deficiency. Continuously high blood sugar levels interfere 
with numerous metabolic processes and, as a consequence, lead to severe tissue damage. 
Only a minority of patients suffers from an absolute insulin deficiency. This so-called Type 1 
diabetes is caused by the complete absence of insulin secondary to autoimmune destruction 
of the insulin-producing islet β-cells in the pancreas (Eisenbarth, Nayak et al. 1988). In the 
vast majority of patients, diabetes is triggered by a combination of genetic and environmental 
factors, which interfere with the body’s ability to react to insulin (type 2 diabetes).  
 
Insulin resistance, a hallmark of Type 2 diabetes is defined as an inadequate response of 
insulin target tissues, such as skeletal muscle, liver, and adipose tissue, to the physiologic 
effects of circulating insulin. The hallmarks of impaired insulin sensitivity in these three 
tissues are decreased insulin-stimulated glucose uptake into skeletal muscle, impaired 
insulin-mediated inhibition of hepatic glucose production in the liver, and a reduced ability of 
insulin to inhibit lipolysis in adipose tissue.  Pancreatic β-cells counteract insulin resistance 
by increasing the production and release of insulin resulting in a compensatory 
hyperinsulinemia (Perley and Kipnis 1966; Polonsky, Given et al. 1988; Kahn, Prigeon et al. 
1993). With time, the progressive deterioration in β-cell function contributes to the 
characteristic relative insulin deficiency and aggravates hyperglycemia (DeFronzo 1997).  
 
Type 2 diabetes is a well characterized disease and has been known for many years. 
Nevertheless, the molecular mechanisms underlying the development of insulin resistance 
are still not fully understood. During the past decade, it became clear that inflammation is a 
key feature of obesity and Type 2 diabetes (Wellen and Hotamisligil 2005). Currently, there 
are two main theories that explain the molecular mechanisms underlying the development of 
insulin resistance. 
 
1.Inflammation. Weight gain during the course of obesity induces low grade chronic 
inflammation in white adipose tissue leading to local insulin resistance and the release of 
pro-inflammatory cytokines such as TNF and IL-6 into the circulation (Hotamisligil, Shargill et 
al. 1993). Inflammatory cytokines inhibit insulin action in classical insulin target tissues such 
as skeletal muscle, liver and adipose cells, thereby resulting in impaired glucose 
homeostasis (Hotamisligil, Budavari et al. 1994; Plomgaard, Bouzakri et al. 2005).  
2.Lipotoxicity. Insulin resistance in the adipose tissue leads to elevated release of lipids into 
the circulation. Once the capacity of the skeletal muscle and liver to dispose fatty acids via 
oxidation or storage is exceeded, various fatty acid intermediates, including Diacylglycerols 
and Ceramides, accumulate in skeletal muscle and liver and negatively regulate insulin 
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action (Bachmann, Dahl et al. 2001; Morino, Petersen et al. 2006; Summers 2006). Nutrient 
sensors like p70S6K and the PKC pathway are activated and lead to an impairment of insulin 
signaling in concert with a subsequent activation of inflammatory signaling pathways like JNK 
and NF-kB (Sathyanarayana, Barthwal et al. 2002; Jean-Baptiste, Yang et al. 2005; 
Sampson and Cooper 2006; Wang, Devaiah et al. 2006). 
 
Graph 5: Obesity, tissue inflammation, and insulin resistance Picture taken from Olefsky et al. JCI 2008 
In summary, inflammatory cytokines including TNF and lipids seem to play an important role 
initiating a chronic low grade inflammatory state in peripheral insulin sensitive organs. Among 
the insulin sensitive tissues, the liver is of central importance for glucose homeostasis. It is 
able to store excess glucose after food intake in the form of glycogen and releases glucose 
produced by glycogenolysis or gluconeogenesis during fasting in order to maintain steady 
blood glucose levels (Gribble 2005). Moreover, the liver is able to inhibit glycogenolysis and 
gluconeogenesis by controlling gene expression or activity of rate limiting enzymes. 
Dysregulation of insulin action in the liver is a key component in the pathogenesis of Type 2 
diabetes. (Saltiel and Kahn 2001). Therefore, it is important to understand the molecular 
basis of chronic inflammatory reactions and the mechanisms that impair insulin signaling, 
especially in the liver.  
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1.5         The cre/ loxP system  
 
As described before, p38α-/- mice are embryonic lethal. To investigate the role of p38α in the 
liver a conditional mouse model had to be utilized which leads to the deletion of p38α after 
embryonic development. Therefore, mice with a liver parenchymal cell specific deletion of 
p38α were generated using the Cre/LoxP system. The Cre/LoxP system is derived from the 
bacteriophage P1 and allows site specific recombination of DNA strands. The system 
consists of an enzyme (Cre) that catalyses recombination of DNA between specific sites 
(LoxP sites). A loxP site is 34 base pairs long and consists of an asymmetric 8 base pair 
sequence that is flanked by 13 base pair palindromic sequences on both sides. These 
palindromic sequences act as binding sites for the Cre recombinase. The recombination then 
occurs in the asymmetric sequence. As a result a reciprocal recombination event may take 
place between two LoxP sites if cre is expressed in a cell. The asymmetric sequence gives 
directionality to the LoxP site. Important for the outcome of the recombination is the spatial 
orientation of two LoxP sites one against the other. If two sites are placed on the same arm 
of the chromosome and have the same direction, the recombination will result in a deletion of 
the DNA region that was located between the LoxP sites. This effect is commonly used in 
genetics in order to introduce mutations or delete gene regions in a controlled and inducible 
manner. The loxP sites are placed at the desired location of the genome by homologous 
recombination. The presence of the mutation or deletion is regulated via transducing Cre into 
cells or via expressing Cre under the control of an inducible or tissue specific promoter.  
In order to delete p38α specifically in hepatocytes p38αFL mice were crossed with mice 
carrying the Alfp cre transgene (Reichardt, Kellendonk et al. 1999). The p38αFL mice carry 
loxP sites flanking exons 2 and 3, which include the ATP-binding site of the kinase domain. 
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1.6        Objectives 
 
In terms of its cellular composition the liver is a heterogeneous tissue and cytokines are key 
messengers orchestrating the numerous important functions to keep the body homeostasis. 
TNF is an important molecule in this complex interplay of different cell types. Therefore, a 
healthy balance of TNF induced signaling is crucial to maintain liver functions. Dysregulated 
cytokine signaling can shift biological responses in an unfavorable direction. This can lead to 
serious impairment in liver functions having an impact on whole body metabolism or lead to 
liver failure. Understanding the functional complexity of the downstream pathways activated 
by TNF signaling could potentially identify novel targets for the treatment of many acute and 
chronic liver diseases. 
Important progress has been made in order to gain some understanding of the functions that 
the signaling cascades activated by TNFR I signaling process. Many functions of the NF-κB 
signaling pathway and JNK MAPK cascade in the liver have been investigated in detail. The 
functions of p38, another MAPK activated upon TNF signaling, are less understood. This is 
partly due to the fact that p38α-/- mice are embryonic lethal, preventing extensive in vivo 
studies.  
Making use of conditional gene targeting, the aim of the thesis was to study the role p38α in 
the liver during acute and chronic inflammatory states, in vivo. Due to the outstanding role of 
TNF in tissue homeostasis, two models that induce significantly elevated levels of circulating 
TNF were chosen to study the role of p38α in different inflammatory conditions in the liver.  
To study the role of the MAPK p38 during the development of acute liver failure, a model of 
bacterial Lipopolyscaacride (LPS) was applied. LPS is one of the most potent TNF inducers 
but usually does not cause hepatocyte apoptosis unless it is co-administered with D-
Galactasoamine (GalN) which specifically blocks transcription in the liver (Decker and 
Keppler 1974; Bradham, Plumpe et al. 1998). The aim of the first part of this thesis was to 
analyze the LPS/TNF induced apoptotic signals in mice specifically lacking p38α in liver 
parenchymal cells.  
In order to study the role in chronic low grade inflammatory states, a model of high fat diet 
induced obesity and insulin resistance was utilized. Type 2 diabetes is a complex 
multifactorial disease triggered by the combination of β- cell dysfunction and insulin 
resistance of target tissues. Insulin resistance results from impaired activation of the 
enzymatic cascade of phosphorylation events in the insulin signaling pathway. Although a 
huge variety of processes involved in the development of insulin resistance has already been 
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described, the underlying exact molecular mechanisms are still to be investigated. Therefore 
the objective of the second part of this thesis was to analyze the role of liver p38α in chronic 
sub-acute inflammatory states caused by high fat diet feeding and its influence on glucose 
homeostasis and insulin sensitivity. 
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2 Material and Methods 
2.1 Material 
 
Solutions: 
Hepatocyte culture medium: High Glucose DEMEM, 5% FCS, Pen/Strep. 
Ketamin-Rompun solution: 5ml Ketamin (10mg/ml), 230µl 2% Rompun. 
Loading Dye DNA: 15% Ficoll 400 in ddH2O, heat to 50 °C then add Organe G ad libidum, 
autoclave. 
Loading Dye Protein 5x (10ml): 1,1ml Tris HCL pH 6,8, 2ml Glycerol, 3,8ml 10% SDS, 
800µl ß-mercaptoethanol. 
NP-40 Lysis Buffer (500ml): 452,5ml ddH2O, 25ml 1M Tris HCL pH 7,5, 15ml 5M NaCL, 
2,5ml NP-40, 1,05g NaF. Before use add 1 tablet Protease and Phospahtase inhibitor to 10 
ml of buffer.  
Running buffer (1l): 30,25g Tris Base, 144,2g Glycine, 10g SDS. pH was not adjusted. 
Starving medium: High Glucose DEMEM, Pen/Strep 
TAE Buffer 25x (10l): 1210g Tris, 0.5l EDTA pH 8,0 500 m, 285,5mL Acetic acid 
Tail Lysis Buffer (1l): 100ml Tris HCL pH 8,5, 20ml 10% SDS, 11,68 NaCL, 1,86g EDTA.  
TBS (10x) 1l: 24,2g Tris Base, 80g NaCl. Adjust pH to 7,6 with 37% HCL 
TBS/T: add 0,1% of Tween to TBS 
Transfer Buffer (1l): 3g Tris Base, 14,3g Glycine, 20% Methanol. Do not adjust pH. 
Oil Red O Solutin: 1,5g Oil Red O dissolved in 300ml Isopropanol over night, then 200ml of 
ddH2O are added. 
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RIPA buffer high salt (50ml): 1ml 1M HEPES, 3,5ml 5M NaCL, 10ml Glycerol, 50µl 1M 
MgCL2, 50µl 500mM EDTA, 50µl 0,1M EGTA, add  ddH2O to 50ml. Before lysis add 1 tablet 
Protease and Phospahtase inhibitor to 10 ml of buffer, 1% NP-40, 0,1mM NaF. 
Material 
Acrylamide: BioRad 30% Acrylamide/Bis solution Ref: 161-0158  
Agarose: BioZym Ref: 840004 
Amonium Persulfate: Sigma, Ref: 
Bornyle: Adsyte Pro, 22 GA 0,9 x 25mm, BD, Ref: 388714 
Chloroform: Applichem 
Collagenase: Collagenase Type II, Worthington, Ref: 4176 Lot: 47D9570 
Culture dish (Collagen coated) 10cm:  
DMEM: Gibco: 4,5g/l glucose, Ref: 41965 
DNA Ladder: PeqLab, Ref: 25-2000 
DNase: Qiagen RNase free DNase set Ref: 79254 
EBSS -CA, -MG: Gibco, Ref: 14155 
EBSS +CA, +MG: Gibco, Ref: 24010 
ECL solution: GE Healthcare, Ref: PRN2209 
ECL plus: GE Healthcare, Ref: PRN2132 
EGTA: AppliChem 
Ficoll 400: AppliChem A4969,0100, 100g 
Films: Amersham Hyperfilm ECL, Ref: 28906837 
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Genotyping Primer :  
Alfp cre: FW: 5’- TCC AGA TGG CAA ACA TAC GC- 3’  REV: 5’ – GTG TAC GGT CAG 
TAA ATT GGA C- 3’ 
p38α: FW: 5’ CTACAGAATGCACCTCGGATG 3’ REV: 5’ AGAAGGCTGGATTTGCACAAG 
3’ REV: 5’ CCAGCACTTGGAAGGCTATTC 3’ 
IKK2: FW: 5’  - GTT CAG AGG TTC AGT CCA TTA TC - 3’ REV: 5’ -  TAG CCT GCA AGA 
GAC AAT ACG - 3’ REV: 5’ - TCC TCT CCT CGT CAT CCT TCG - 3’ 
HEPES 1M: Gibco, Ref: 15630-056 
Insulin: Insuman Rapid, 40 I.E./ml Sanofi Aventis 
Insulin assay kit (serum): Chrystal Chem, Ref: INSKR020 
Ketamin: Ketamin-Ratiopharm 50mg (10mg/ml) 
LPS: Sigma 
NaCl: Sigma 
Nylon mesh: Falcon Cell strainer, BD, Ref: 352350 
Oil Red O: AppliChem 
Orange G: AppliChem A1404,0025 25 g 
Penceau S: ApplicChem Ref: A2935 
Protein Marker: PeqGold Protein Marker V, PeqLab, Ref: 27-2210 
Phospatase inhibitor: PhosStop, Roche, Ref: 04 906 837 001 
Protease Inhibitor: Complete Mini, EDTA free, Roche, Ref: 04 693 159 001 
PVDF membrane: Immobilon P, Millipore, Ref: IPVH00010 
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Rompun 2%: Bayer Healthcare 
RNA isilation Kit: Qiagen, RNeasy Mini, Ref: 74104 
RT kit: SuperScript III Invitrogen Ref: 18080-051 
SDS: AppliChem 
Taquman Master mix:  
Applied Biosystems, Taqman Gene Expression Master Mix, Ref: 4369016 
Taquman Probes:  
TNF: Mn00443258_m1 
MCP-1: Mn00441242_m1 
IL-6: Mn00446190_m1 
IL1β: Mn00434228_m1 
Gapdh: Mn99999915_g1 
TEMED: Merk 
Trizol: Invitrogen, Ref: 15596-018 
Trypan Blue 0,4%: Sigma, Ref: T8154 
Trypsin inhibitor: Sigma T9128 
Tween: Tween 20, Sigma-Aldrich Ref: P1379 
Tunnel Kit: DeadEnd Fluorometric TUNEL System, Promega, Ref: 63250 
Tris: Sigma 
Western Blot stripping buffer: Thermo scientiffic, Ref: 21059 
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Tools/machines: 
Gel chamber WB: BioRad 
Glucomen: GlucoMen Visio, A.Menarini Ref: Ref: 36364 
Glucomen Test stripes: A.Menarini Ref: 36364 
Homogenizer: Precellys 24, PeqLab Ref: 91-PCS24 
Nanodrop: PeqLab Ref: 91-ND-2000 
Pump: Masterflex Easy load II, Cole&Parmer, Model: 77202-50 
RT machine: 7900 Fast Real Time PCR System Applied Bilsosystems 
Clinical analyzer: Cobas 1001 (Roche) 
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2.2 Methods 
2.2.1 Molecular biology 
 
2.2.1.1       Preparation of genomic DNA from tail biopsies of mutant mice 
Tails biopsies were lysed in tail lysis buffer rotating at 56 °C for minimum 2 hours. The cell 
debris was spun down for 5 min at 14000rpm and the supernatant was mixed 1:1 with 
isopropanol to extract the DNA. The DNA was precipitated by centrifuging for 5 min at 
14000rpm. After discarding the supernatant the pellet was washed with 500µl of 70% Ethanol 
were added. The samples were spun at 14000rpm for 5 minutes, air dried for 10 minutes at 
room temperature and resuspended in 100µl ddH2O. 2µl of DNA were used for each PCR 
reaction. 
 
2.2.1.2       Polymerase chain rection (PCR) 
The polymerase chain reaction (PCR) was used for amplification of DNA fragments in vitro 
for mouse genotyping (Saiki, Scharf et al. 1985). Genotyping of mice was performed in a 
total reaction volume of 25 μl containing a maximum of 500 ng template DNA isolated from 
tail biopsies, 25 pmol of each primer.  
 
2.2.1.3       Agarose gel electrophoresis and DNA gel extraction 
PCR-amplified and digested DNA fragments were separated by size using agarose gel 
electrophoresis [1 to 3% (w/v) agarose (depending on fragment size); 1 x TAE; 0.5 mg/ml 
EtBr; 1 x TAE electrophoresis buffer]. 1 x TAE electrophoresis buffer was used as running 
buffer. 
 
2.2.1.4       RNA isolation 
Frozen pieces of liver tissue were placed in a tube with ceramic beads. 1ml of Trizol was 
added and the tissue was homogenized in a tissue homogenizer (Precellys 24, PeqLab) at a 
speed of 6800rpm for 20 seconds. The homogenized samples were spun at 4 °C, 12000g for 
10 minutes. The supernatant was taken and mixed with 200µl of Chloroform. The tubes were 
mixed vigorously for 15 seconds and incubated at room temperature for 2 minutes, then 
centrifuged for 15 minutes, at 4 °C, 12000g. The upper colourless phase containing the RNA 
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and DNA was transferred into a new tube and 600µl of 70% EtOH were added to yield a 1:1 
dilution. The RNA and DNA were bound on columns from the RNEasy isolation Kit (Qiagen) 
and centrifuged 15 seconds, at 4 °C, 9000g. The column was washed once with 350µl of 
RW1 buffer followed by an on column DNA digestion with DNAse (Qiagen Dnase Kit) for 15 
minutes at room temperature. After the DNAse digest the column was washed again with 
350µl RW1, then twice with 500µl of RPE buffer. Between the washes centrifugation steps 
for 15 seconds, at 4°C, 9000g were carried out. After washing, the columns were placed in 
fresh collection tubes and spun at full speed for 2 minutes. The RNA was eluted twice in 30µl 
of RNase free water. The quality of isolated RNA was assessed by electrophoresis on 
denaturing agarose gels (1.2% (w/v) agarose; 1 x MOPS; 1% (v/v) formaldehyde; 1 x 
MOPSelectrophoresis buffer). To determine possible DNA contaminations a PCR for actin 
was performed with 1 µg of RNA.  
 
2.2.1.5       cDNA synthesis 
1µg of RNA was used to synthesize cDNA using the first strand RNA synthesis Kit 
(Invitrogen). The RNA was mixed with 1µl 10mM dNTP mix and 1µl 50ng/µl random hexamer 
mix. Water was added to a final volume of 10µl. The sample was incubated at 65°C for 5 
minutes and placed on ice. The reaction mix containing 2µl of 10 RT buffer, 4µl 25mM 
MgCl2, 2µl 0,1 mM DTT, 1µl RNase out and 1µl SuperScript RT was added. The reverse 
transcription reaction was carried out starting with an incubation for 10 minutes at 25°C 
followed by 50 minutes at 50°C. The reaction was terminated at 85°C for 5 minutes. 1µl of 
RNase was added to digest the RNA at 37°C for 20 minutes. The cDNA was diluted in 180µl 
of water and successful cDNA synthesis was verified with a PCR for actin using 2µl of each 
cDNA sample.  
 
2.2.1.6       Quantitative PCR 
qPCR reactions were carried out in a 384 well plate. 2µl of cDNA, 3,4 µl of water, 0,6 µl of 
primer mix (Applied Biosystems) and 6 µl of Taqman master mix (Applied Biosystems) were 
used per reaction. Samples were run in duplicate with a non template control for each primer 
set. Dilutions, namely 1:4, 1:16, 1:64, with a positive cDNA were run as a control. 
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2.2.2 Cell biology 
 
2.2.2.1       Isolation of primary hepatocytes 
Prior to the isolation, the pump was rinsed with 70% Ethanol followed by a short rinse with 
deionized water. Solution I (EBSS without Ca2+ and Mg2+, 0,5ml 0,5M EGTA), and solution II 
(EBSS with Ca2+ and Mg2+, 5ml of 1M HEPES), were prepared, kept at 4°C and warmed up 
to 40°C in a water bath prior to use. 15mg of Collagenase and 2mg Trypsin inhibitor (Sigma) 
were placed in a 50 ml falcon tube. A cell culture centrifuge was cooled down to 4°C before 
starting the procedure. 
The mice were anesthetized by intraperitoneal injection of Ketamin/Rompum (~12µl/g bw). 
Once the mice were unconscious and resistant to a toe pinge test, the peritoneal cavity was 
opened and the organs pushed aside in order to expose the vena cava. The boryle was 
inserted through the vena cava and the portal vein was cut prior to perfusion. The mice were 
perfused via the vena cava with solution I at a speed of 6 for 5 minutes. The tube containing 
the collagenase and trypsin inhibitor was filled with 50 ml of solution II. Subsequently, 
perfusion with 50 ml of collagenase (Worthington/Cell systems) solution (EBSS with Ca2+ and 
Mg2+, 10 mM Hepes, 3810 U collagenase and 2 mg Trypsin inhibitor) was performed. After 
perfusing with 50ml collagenase solution at a speed of 4-5, the liver was taken out carefully 
and the gallbladder was excised. A single cell suspension from the perfused liver was 
generated by carefully breaaking the capsule of the liver and filtering the suspension through 
a 70 μm nylon mesh. Hepatocytes were washed 3 times in high glucose DMEM 
supplemented with 5% FCS. 3 x 106 cells were seeded on collagen coated 10 cm dishes. 4h 
after isolation, the medium was changed.  
 
2.2.2.2       Hepatocyte culture 
Primary hepatocyteswere cultured in DMEM GlutaMAXTM I (Gibco) supplemented with 5% 
(v/v) FCS (Gibco), 100 U/ml penicillin (Gibco), 100 μg/ml streptomycin (Gibco), and 1 mM 
sodium pyruvate(Gibo) at 37°C in an atmosphere of 5% CO2 and 95% humidity. The 
medium was changed every day. Hepatocytes were cultures for a maximum of 2 days 
 
2.2.2.3       Insulin Signaling in vitro 
Primary hepatocytes were cultured over night. Cells were starved in serum free medium for 4 
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hours. 200mM of insulin (Sigma) were added to the cells for 2, 5 or 10 minutes. The cells 
were then washed with 10ml of ice cold PBS, scraped off the plate with 1ml of ice cold PBS, 
washed once with PBS and frozen in liquid nitrogen. 
 
2.2.3 Biochemistry 
 
2.2.3.1       Lysis of tissue samples with NP-40 Buffer  
Tissue samples were homogenized in a tissue homogenizer (Precellys 24, PeqLab) using 
600µl of NP-40 Buffer. Soft tissues including liver and fat were homogenized at 6800rpm for 
20 seconds while muscle tissue was homogenized at 6800rpm for 2x20 seconds. During this 
process the samples were kept at 4°C. The cell debris was spun down at 13000rpm at 4°C 
for 10 minutes. A Bradford assay was used to determine the protein concentration of the 
samples. 
 
2.2.3.2       Lysis of hepatocytes with high salt RIPA buffer 
Cell pellet (from 10cm dish) was dissolved in 350µl of RIPA buffer, vortexed and incubated 
on ice for 30 minutes. The cell debris was collected by spinning at maximum speed for 20 
minutes at 4°C.. Supernatant was taken off. The protein lysate was sonicated for 7 minutes 
4°C in a water bath sonicator. A Bradford assay was used to determine the protein 
concentration of the samples. 
 
2.2.3.3       Bradford assay 
For the measurement of protein concentration, tissue samples were diluted 1:10 in lysis 
buffer. Standard BSA concentrations of 5, 2,5, 1,25 and 0,675 µg/µl were measured to 
generate a standard curve. 1 µl of each sample was mixed with 1 ml of Bradford solution, 
incubated for 5 minutes and measured with a spectrometer. Protein concentrations were 
calculated with the standard curve and samples with equal concentration were generated 
and boiled with loading dye at 96°C for 3 minutes. 
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2.2.3.4       Immunoblot analysis  
Protein samples were separated on a 10% SDS-polyacrylamide gel by electrophoresis 
(PAGE) with a current of 100V. After separation, the protein was transferred to a 
nitrocellulose membrane that had been previously activated with methanol, at a maximum 
current of 20V (80mA per gel) for 2 hours, using a semi.dry blotting system. For proteins 
>100 kDa a wet blotting system was used transferring the protein at a current of 80V for 2,5 
hours. The membranes were probed with antibodies specific for: Tubulin α (Sigma), p38α, 
IKK2, c-jun, phospho-c-jun, JNK, phospho -JNK, cleaved caspase 3, total caspase 3, 
phospho -MKK7, MKK7, phospho -MKK4, MKK4, MKK3, phospho -MKK3/6, p38δ, IκBα, 
phospho -Akt, Akt, phospho -ERK1/2, ERK1/2 (Cell Signaling), c-FLIP (Alexis), p38β, 
phospho-IκBα, MKP1, MKP2, MKP3 (Santa Cruz) pp5 (BD), pp1me (ABGENT), pp1a 
(Biozol), pp2a (Upstate). HRP-conjugated anti-rabbit, anti-mouse and anti-rat secondary 
antibodies were used (Amersham). 
 
2.2.3.5       Stripping of PVDF membranes 
The membranes were washed with deoinized water for 5 minutes shaking at room 
temperature, incubated for max. 5 minutes in 0,2M NaOH and washed with deoinized water 
twice for minutes. 
 
2.2.3.6       Electromobility shift assay (EMSA).  
In order to investigate Protein-DNA interactions, nuclear proteins were incubated with a 
radioactively labeled oligonucleotide and subsequently separated by electrophoresis. The 
sequence of the oligonicleotide was chosen to have a specific binding sequence for the 
protein. In this case a 32P-labelled oligonucleotide representing an NF-κB consensus site 
(5’-CGG GCT GGG GAT TCC CCA TCT CGG TAC-3’) was used as a probe. In order to be 
able to identify the complexes on the gel, antibodies which are able to bind the protein-DNA 
complex were used. The Protein-DNA complexes were then identified by their altered 
migration on the gel (supershift). For each sample 2-5 µg of nuclear protein was used. 
Protein samples were incubated in a reaction mix with a total reaction volume of 20µl 
containing 5µl 5x binding buffer, 1µl Poly(dI-dC), 1µl BSA 10 μg/μl indH2O, 2 μl 10x 
proteinase-inhibitor cocktail and 50.000cpm [32P] labeled Oligonucleotide for 30 minutes on 
ice. For supershift analysis antibodies were added after the incubation for 30 minutes (p50, 
p65, c-Rel and RelB from Santa Cruz Biotechnology). Then, 2µl loading buffer (20% Ficoll 
suspension) were added and the probes were loaded on the 5% acrylamide gel. Samples 
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were run at 4°C. After 20 minutes the current was raised from 200V to 300V. The separation 
time was 3 hours in total. The gel was fixed for 15 minutes in 20% Methanol/10% acetic acid 
and subsequently dried under vacuum. The dry gel was exposed to a film at -80°C for 
several days. 
 
2.2.3.7       Histology 
Cryo sections 
For cryo sections tissues were embedded in tissue freezing medium (Jung Tissue Freezing 
medium, Leica Microsystems) and frozen on dry ice. Later, the frozen blocks were 
transferred to -80°C. Prior to sectioning the frozen blocks were placed at - 20°C for several 
hours. Standard thickness for paraffin sections was 7µm. For Oil red O liver stainings 12µm 
sections were cut. 
Paraffin sections 
Tissues were fixed in 4% paraformaldehyde over night at 4°C. After fixation the samples 
were placed in PBS at 4°C until embedding in Paraffin. 
H&E Staining 
Sections were deparaffinized in Xylol for 20 minutes. Then the samples were hydrated in 
100% Ethanol for 2 minutes, followed by 2 minutes of 90% Ethanol and 2 minutes of 75% 
Ethanol. The sections were washed in PBS briefly and 1 minute in tap water. Next, sections 
were incubated in Haematoxylin for 6 minutes (liver) followed by a short wash in warm water 
and a short wash in deionized water. The samples were incubated in Eosin solution for 1 
minute, then washed 6 to 7 times in tap water. Next, sections were dehydrated in 75% 
Ethanol for 1 minute, followed by 1 minute of 90% Ethanol and 1 minute of 100% Ethanol. 
The sections were then incubated in Xylol for 1-5 minutes and mounted with Eukitt. 
Oil red O staning 
Cryo sections were washed in tap water for 5 minutes. After washing the sections were 
stained with Oil red O solution for 15 minutes then quickly rinsed with tab water. The sections 
were counterstained for 6 minutes with Haematoxylin solution. The stained sections were 
washed with water for 15 minutes then mounted with Glyceringelatine. 
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2.2.3.8       TUNEL assay 
The TUNEL test was performed using the “In situ cell death detection Kit” (Roche 
Diagnostics) Sections were fixed in 4% PFA dissolved in PBS for 30 minutes at room 
temperature. After fixation the sections were washed twice in PBS (once short, than 5 
minutes). Next, the sections were incubated with Proteinase K (from Kit) diluted 1:1000 in 
Tris/EDTA buffer (100mM Tris pH 8/HCL 80mM EDTA) using a moist chamber for 30 min at 
room temperature. After the Proteiniase K digest, the sections were washed 2 x in PBS for 5 
minutes and then permeabilized with Triton (0,1%Triton in 0,1% Na-Citrat) for 15 minutes. 
The sections were then washed again 2 x in PBS for 5 minutes. Excess liquid was removed 
and slides were equilibrated with 100 ul of Equilibration Buffer for 10 minutes. While the cells 
were equilibrating, the reaction mix was prepared on ice: Equilibration Buffer 45 ul, 
Nucleotide Mix 5 ul, TdT Enzym1µl (per reaction). The mix was added on the slides which 
were covered with Plastic Coverslips (from Kit) for 60 minutes at room temperature in a 
chamber with aluminum foil. The slides were then incubated in 2x SSC for 15 minutes to 
terminate the reactions. After terminating the reaction, the slides were washed 3x in PBS for 
5 minutes, then mounted with Vectashild and DAPI. 
 
2.2.3.9       Lipid Analysis (Thin layer Chromatography) 
The mouse liver content of cholesterol, cholesteryl esters and triacylglycerols was analyzed 
by Thin Layer Chromatography. Samples of mouse liver tissue (50 to 150 mg) were 
homogenized with the Homogenisator Precellys 24 (Peqlab) in 1 ml of water at 6.500 rpm for 
30 seconds. The protein content of the homogenate was routinely determined using 
bicinchoninic acid. After addition of 4 ml of methanol and 2 ml of chloroform, lipids were 
extracted for 24 h at 37°C. The liquid phase was separated by filtration, and the insoluble 
tissue residues were further extracted for 24 h at 37°C in 6 ml of methanol/chloroform 1:1 
(v/v) and finally 6 ml of methanol/chloroform 1:2 (v/v). The extracts were combined, and the 
solvent was evaporated under a stream of nitrogen. The residues were purified using a 
modification of the Bligh-Dyer procedure as previously described (Signorelli and Hannun 
2002). Lipids were applied to 20 × 10 cm high performance thin layer chromatography 
(HPTLC) Silica Gel 60 plates (Merck), which were pre-washed twice with 
chloroform/methanol 1:1 (v/v) and air-dried for 30 min. For quantification of triacylglycerols 
and cholesteryl esters, each lane of the TLC plate was loaded with the equivalent of 50 μg 
and 1 mg wet weight of liver tissue, respectively. The TLC solvent system used was 
hexane/toluene 1:1 (v/v), followed by hexane/diethyl ether/glacial acetic acid 80:20:1 (v/v). 
For quantitative analytical TLC determination, increasing amounts of standard lipids (Sigma-
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Aldrich) were applied to the TLC plates in addition to the lipid samples. For detection of lipid 
bands, the TLC plates were dipped into a phosphoric acid/copper sulfate reagent (15.6 g of 
CuSO4(H2O)5 and 9.4 ml of H3PO4 (85%, w/v) in 100 ml of water) and charred at 180°C for 
10 min (Yao and Rastetter 1985). Lipid bands were then quantified by densitometry using the 
TLC-Scanner 3 (CAMAG), at a wavelength of 595 nm. 
 
2.2.4 Mouse analysis 
 
2.2.4.1       Animal care 
Care of all animals was within institutional animal care committee guidelines. All animal 
procedures were conducted in compliance with protocols and approved by local government 
authorities (Bezirksregierung Köln, Cologne, Germany). Animals were either fed normal 
chow (Teklad Global Rodent 2018; Harlan) containing 53.5% carbohydrates, 18.5% protein, 
and 5.5% fat (12% of calories from fat) or a HFD (C1057; Altromin) containing 32.7% 
carbohydrates, 20% protein, and 35.5% fat (55.2% of calories from fat). All mice were kept in 
individual ventilated cages (IVC) in the animal facility of the Institute for Genetics in Cologne. 
All experiments were performed according to EU, national and institutional guidelines. For 
the metabolic project bodyweight was measured once a week. 
 
2.2.4.2       Generation of conditional knockout mice 
p38αFl (Heinrichsdorff et al., 2008), NEMOFl mice (Schmidt-Supprian et al., 2000) and IKK2Fl 
mice (Pasparakis et al., 2002) were crossed to Alfp-Cre transgenic mice (Kellendonk et al., 
2000) to generate liver parenchymal cell-specific knockout of the respective gene (p38αLPC-KO 
, NEMOLPC-KO and IKK2LPC-KO mice). p38α/IKK2 double mutant mice were generated by 
crossing p38αLPC-KO mice to IKK2Fl/Fl mice (p38α/IKK2LPC-KO).  
 
2.2.4.3       Genotyping of mutant mice 
PCR reaction volume: 30 µl 
 1 reaction 
Buffer 10x 3 µl 
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dNTPs 2mM 
Primer mix 10x (33 µM each) 
MgCl2 25mM  
DNA 
Taq 5 U/µl 
dd-Water 
3 µl 
3 µl 
1,8 µl (f.c.1,5mM) 
2 µl 
0,2 µl 
17 µl 
Program Alfp cre/IKK2: 
94°C     3 min  
94°C     30 sec 
60°C     30 sec 
72°C     30 min 
 
    35x 
Program p38α : 
94°C     3 min  
94°C     30 sec 
62°C     30 sec 
72°C     30 sec 
 
    35x 
72°C      2 min  
2.2.4.4       Liver injury models 
Experiments were performed on male mice between 8 and 10 weeks of age. LPS (Sigma) 
was administered i.p. at 25µg/10g of body weight. Mice were bled before and 4 hours after 
the injection by submandibular bleeding. 10 hours after the injection the mice were sacrificed 
and blood was taken from the heart. 
2.2.4.5       Antioxidant treatment 
For antioxidant treatment mice were fed a diet containing 0,7% butylated hydroxyanisole 
(BHA) (Sigma) for 3 days before LPS injection. 
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2.2.4.6       Submandibular bleeding 
The superficial temporal vein runs diagonally across the face from above the orbit toward the 
base of the ear.  
 
The animals were manually restrained with the lateral surface of the hand facing the person 
holding the mouse. The lancet (Goldenrod Animal Lancet) was held in the other hand. A stab 
incision into the cheek was made, approximately halfway between the ear and the mandible. 
The blood was collected into a tube. After bleeding the mouse was released from the restrain 
and a compression was applied to the cheek for 5 seconds. After the procedure the mice 
were monitored for 5 minutes to ensure that the bleeding had stopped. For mice <20 grams 
4mm lancets were used, for mice between 20-40 grams 5mm lancets and for mice >40 
grams 6mm lancets were used.  
 
2.2.4.7       Serum analysis 
Mice were bled from the tail vein or by submandibular bleeding. The blood was stored at 4 
°C for 10 minutes then centrifuged for 5 minutes at 6000g at 4°C. The serum was taken off 
and analyzed with the Cobas 1001 Clinical analyzer (Roche) (GOT, GPT, Chlesterol, 
Triazylglycerides) or by ELISA (insulin). 
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2.2.4.8       Glucose tolerance test 
Glucose tolerance tests were performed on animals that had been fasted for 16 hours. 
Animals were injected with 2g/kg bodyweight of glucose into the peritoneal cavity. Blood 
glucose concentrations were determined before, 15, 30 60 and 120 minutes after the 
injection of glucose. Blood was taken from a small tail biopsy and glucose content was 
measured using an automated glucose monitor (Glucoman) for the indicated time points. 
 
2.2.4.9       Insulin tolerance test 
0,75 U/kg bodyweight of human regular insulin (Insuman Rapid, Sanofi Aventis) was injected 
into the peritoneal cavity. Blood glucose concentrations were determined before, 15, 30 60 
and 120 minutes after the injection of glucose. Blood was taken from a small tail biopsy and 
glucose content was measured using an automated glucose monitor (Glucoman) for the 
indicated time points. 
 
2.2.4.10      Insulin signaling, in vivo 
Mice were anesthetized by intraperitoneal injection of Ketamin/Rompum (~12µl/g bw) 5 mU. 
The peritoneal cavitiy was opened to expose the vena cava. Human regular insulin (Insuman 
Rapid, Sanofi Aventis) was injected into the inferior vena cava. Liver, muscle and adipose 
tissue were collected 2, 5 and 7 minutes after injection and processed as previously 
described to determine insulin mediated signaling by immunoblot analysis. 
 
2.2.4.11     Measurement of serum insulin concentrations.  
Plasma insulin concentrations were examined by ELISA (Chrystal Chem, BD Bioscience 
PharMingen). Each well of the microplate was washed twice with wash buffer. 50µl guinea 
pig anti-insulin serum were dispensed per well. Then, 45µl of sample diluent and 5µl of 
sample (or 5µl working insulin standard) were given in the wells. The microplate was 
incubated overnight at 4 °C. After incubation, the wells were washed three times with wash 
buffer. 100 µl of anti-guinea pig antibody enzyme conjugate were given into every well, 
followed by incubation for 3 hours at room temperature. The wells were then washed 5 times 
with wash buffer solution. 100µl of enzyme substrate solution were dispensed per well. The 
microplate was incubated for 30 minutes at room temperature while avoiding exposure to 
light. The reaction was stopped by adding 50µl of enzyme reaction stop solution per well and 
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the plate was measured immediately at A492. A630 values were subtracted. Insulin 
concentration was calculated by the standard curve. 
 
2.2.4.   Analysis of body composition by NMR 
Lean mass and body fat content of live animals was determined using the NMR Analyser 
Minispec (Bruker Optik). 
 
2.2.5 Statistics. 
 
 Results are expressed as the mean +/- standard error of the mean (SEM). Statistical 
significance between experimental groups was assessed using an unpaired two-sample 
Student t-Test. 
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3 Results 
 
3.1 Generation of mice with a liver parenchymal cell specific deletion of p38α 
 
In order to delete p38α specifically in hepatocytes p38αFL mice were crossed with mice 
carrying the Alfp cre transgene (Reichardt, Kellendonk et al. 1999). The p38αFL mice carry 
loxP sites flanking exons 2 and 3, which include the ATP-binding site of the kinase domain 
(Fig. 1 A). At this point it should be mentioned that “FL” is the term for “floxed” which is used 
in this thesis and describes mice carrying loxP sites in both alleles. Cre is expressed under 
the control of both the mouse albumin regulatory elements and the α-fetoprotein enhancer 
and leads to cre expression exclusively in hepatocytes and bile duct epithelial cells. By 
crossing p38αFL mice with Alfp cre positive mice p38αLPC-KO mice were obtained that had a 
deletion of p38α specifically in hepatocytes and bile duct epithelial cells. 
 
 p38αLPC-KO mice were born at the expected Mendelian ratio, were viable and fertile, and did 
not show signs of hepatic alterations. The generation of p38αLPC-KO mice results in efficient 
deletion of p38α in the liver of these mice which was shown by immunoblot analysis (Fig. 1 
B). However, some expression of p38α was retained owing to the presence of non-
parenchymal cells such as Kupffer and endothelial cells that are not targeted by the Alfp-Cre 
transgene. In order to check if there was compensatory elevation of p38ß and p38δ, 
immunoblot analysis of liver extracts from p38αLPC-KO and wild type mice was performed. As 
seen in Fig. 1 C, expression levels of p38 δ did not change due to the p38α knockout, while 
p38ß was not detected. 
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Figure 1: Liver parenchymal cell specific deletion of p38α. (A) Schematic description of the targeting strategy 
for the generation of mice with loxP-flanked p38α alleles. Filled boxes indicate the loxP-flanked exons 2 and 3 
(E2, E3), which include the ATP-binding site of the kinase domain. B, BamHI; H, HindIII. Black arrowheads 
indicate loxP sites; white arrows indicate FLP recombinase target (Frt) sites. (B) Immunoblot analysis of p38α 
expression in liver extracts from wild-type (WT) and p38αLPC-KO mice. (C) Immunolot analysis of p38ß and p38δ in 
liver extracts from wild-type (WT) and p38αLPC-KO mice. 
A 
 
B 
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3.2 The role of liver p38α in a model of LPS/TNF induced liver toxicity 
3.2.1 p38αLPC-KO mice are not sensitive to LPS-induced liver failure 
 
In order to examine the function of liver p38α in cytokine induced signaling, p38αLPC-KO and 
littermate control mice were injected with 25µg/10g LPS into the peritoneal cavity. For all 
experiments described here, littermates carrying loxP-flanked p38α alleles but lacking 
expression of Cre recombinase were used and were termed wild-type or control animals. 
Liver damage was assessed by measuring serum aminotranferases which are quickly 
released into the circulation upon hepatocyte death (Fig. 2 A). Moreover hepatocyte 
apoptosis was measured by TdT-mediated dUTP nick end labelling (TUNEL) of liver sections 
(Fig 2 B) and by immunoblot  analysis of caspase 3 activation in liver extracts (Fig. 2 C). 
Figures 2 A-C clearly show that the deletion of p38α does not lead to increased hepatocyte 
apoptosis compared to control animals after LPS injection. In contrast to that, as shown 
previously (Luedde, Beraza et al. 2007), the deletion of NEMO in liver parenchymal cells 
results in much higher sensitivity to LPS induced hepatocyte death (Fig. 2 B and C) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: p38αLPC-KO mice are not sensitive to LPS-induced liver failure. Assessment of liver damage in (A) 
p38αLPC-KO and control mice after LPS injection. Levels of free circulating alanine aminotransferases (ALTs) were 
measured in the serum of p38αLPC-KO and control mice at the indicated time points after LPS injection. Error bars 
denote s.e.m. (n>4).  
 
 
 
 
 
 
A 
Results
 
56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: p38αLPC-KO mice are not sensitive to LPS-induced liver failure. (B) Detection of apoptotic cells by 
TUNEL assay in livers from wild-type, p38αLPC-KO and NEMOLPC-KO (used as a positive control) mice 10 h, after 
LPS injection. (C) Immunoblot analysis of caspase 3 activation using an antibody that specifically detects the 
cleaved form in protein extracts generated from WT and p38αLPC-KO mice. NEMOLPC-KO mice that are characterized 
by complete inhibition of canonical NF-κB signaling in the liver, are used as positive control (Fig 2 B, C).  
 
3.2.2 Increased activation of JNK in p38α-deficient livers 
 
Sustained activation of JNK has been shown to be essential for TNF -induced killing of NF-
kB-deficient liver cells (Kamata et al, 2005; Chang et al, 2006). Therefore, the status of JNK 
activation in p38α-deficient and control livers was investigated after LPS injection. 
Surprisingly, JNK activation was strongly increased in livers from p38αLPC-KO mice compared 
with control mice after LPS administration (Fig. 3 A). In contrast, NEMO-deficient livers that 
are highly apoptotic, did not show a hyperactivation of JNK compared to control livers (Fig. 3 
B). Consistent with JNK activation, c-Jun phosphorylation was also induced in livers from 
p38αLPC-KO mice after LPS injection (Fig. 2 C). Thus, although pJNK levels are massively 
       B     
 
       C  
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increased in the livers of p38αLPC-KO mice after LPS injection, these livers are not sensitized to 
LPS induced toxicity. Thus, sustained JNK activation in response to TNF signaling does not 
seem to be sufficient to cause hepatocyte death in p38α deficient livers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3: Increased activation of JNK in p38α-deficient livers. (A) Phosphorylation of JNK was assessed in 
liver extracts from wild-type and p38αLPC-KO mice that were injected with 25µg/10g body weight LPS for the 
indicated times, by immunoblot analysis using phospho-JNK-specific antibodies (upper panel). JNK immunoblot 
acts as loading control. (B) Immunoblot analysis detecting the phosphorylation of JNK in NEMOLPC-KO and control 
(WT) mice. (C) Immunoblot analysis with antibodies recognizing phosphorylated c-Jun (upper panel), total c-Jun 
(middle panel) and Tubulin (lower panel) as loading control. 
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3.2.3 LPS does not induce increased activation of the NF-κB, ERK and AKT survival 
            pathways in p38αLPC-KO livers 
 
In order to assess if an increased activation of survival pathways contributes to the survival 
of hepatocytes in p38α deficient cells despite massive activation of JNK, the activation of NF-
κB, extracellular signal-regulated kinase (ERK) and AKT was measured. Activation of NF-κB, 
shown by immunoblot analysis of IκBα phosphorylation and degradation was similar in the 
livers of LPS injected p38αLPC-KO and control mice (Fig. 4 A). Moreover, neither the activation 
of ERK, nor the activation of AKT in response to LPS injection differed between p38αLPC-KO 
mice and control mice (Fig. 4 A and B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: LPS does not induce increased activation of the NF-κB, ERK and AKT survival pathways in 
p38αLPC-KO livers. (A) Immunoblot analysis of liver extracts from wild-type  and p38αLPC-KO mice after LPS injection 
at the indicated time points assessing NF-κB and ERK activation using antibodies against the phosphorylated 
form of pIκBα, IκBα, pERK 1/2 and ERK. Actin serves as a loading control. (B) Specific antibodies were used to 
detect pAKT to measure AKT activity after LPS injection. Tubulin and AKT serve as  loading control. 
                                 A 
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3.2.4 Decreased c-Flip (L) levels in the livers of NEMOLPC-KO mice, but not in p38αLPC-KO  
            mice 
 
In order to find the reason why LPS induced TNF signaling is not able to kill p38α-deficient 
hepatocytes despite the massive activation of proapoptotic JNK, the effects of p38α ablation 
on downstream mediators of JNK function were examined. Previously, it was reported that 
JNK facilitates TNF-induced apoptosis by promoting the proteasome-mediated degradation 
of the long c-FLIP isoform c-FLIP (L), an inhibitor of caspase 8, the expression of which is 
regulated by NF-κB (Micheau, Lens et al. 2001; Chang, Kamata et al. 2006). Immunoblot 
analysis was performed on livers taken from p38αLPC-KO, NEMOLPC-KO and control mice after 
LPS injection. c-FLIP(L) levels were assessed, showing a slight down regulation of c-FLIP (L) 
protein 4 h after LPS injection in livers taken from p38αLPC-KO mice compared to livers from 
control mice (Fig 5 A). However, 10 h after injection of LPS, the levels of c-FLIP(L) were 
similar in p38αLPC-KO and control mice (Fig 2 A). By contrast, the levels of c-FLIP (L) were 
diminished in NEMO deficient livers 10 h after LPS injection (Fig. 5 A, lanes 7–9), which is 
consistent with the increased hepatocyte apoptosis detected at this point. These results 
show that even a massive activation of JNK is not sufficient to reduce intracellular levels of c-
FLIP (L) below the threshold required to sensitize hepatocytes to TNF-induced death. On the 
other hand, even a moderate prolongation of JNK activity results in degradation of c-FLIP(L) 
and apoptosis of hepatocytes with defective activation of NF-κB.   
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Decreased c-Flip levels in the livers of NEMOLPC-KO mice, but not in p38αLPC-KO mice. The levels of c-
FLIP (L) in WT, p38αLPC-KO and NEMOLPC-KO mice were analyzed by immunoblotting at the indicated time points after 
LPS injection using specific antibodies against c-Flip (L). Tubulin acts as loading control. 
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3.2.5 Oxidative stress and MAP kinase phosphatases are not involved in the 
            hyperactivation of JNK in livers of LPS injected p38αLPC-KOmice 
 
In NF-κB-deficient hepatocytes, accumulation of reactive oxygen species is one of the main 
contributing factors that leads to the up regulation of JNK caused by TNF, which can lead to 
the oxidation of JNK phosphatases (Kamata et al, 2005). To test the influence of oxidative 
stress, the antioxidant compound butylated hydroxyanisole (BHA) was administrated in the 
chow diet 48 hours before LPS injection.  
Nevertheless, the BHA treatment did not lead to a substantial reduction of LPS-induced JNK 
activation in p38αLPC-KO mice (Fig. 6 A), suggesting that the mechanism leading to increased 
JNK activation in p38α-deficient livers does not depend on oxidative stress. In addition, 
immunoblot analysis detecting a panel of phosphatases that have previously been reported 
to dephosphorylate JNK showed no differences in protein levels between control and p38α-
deficient livers (Fig. 6 B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Oxidative stress and MAP kinase phosphatases are not involved in the hyperactivation of JNK 
in livers of LPS injected p38αLPC-KOmice (A) Control (WT; lanes 1–3), p38αLPC-KO (lanes 4–6) and p38αLPC-KO mice 
that had been pretreated with the antioxidant compound BHA (lanes 7 and 8) were injected with LPS and 
sacrificed at the indicated time points. Immunoblot analysis was carried out on extracts of liver protein using 
antibodies against phosphorylated JNK or total JNK proteins.  
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Figure 6: (C) Analysis of phosphatase expression in livers from control and p38αLPC-KO mice. (B) Hepatocyte 
expression of MAP kinase specific phosphatases MKP1, MKP2 and MKP3 at steady state and after LPS injection 
at the indicated time points was assessed by immunoblot analysis using specific antibodies. (C) Hepatic 
expression of phosphatases involved in stress responses. Expression levels of pp5, pp1me pp1a and pp2a were 
       B   
          
       C 
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monitored using immunoblot analysis at steady state levels and after injection of LPS at the indicated time points. 
Tubulin serves as loading control. 
3.2.6 LPS induced hyperactivation of MKK4, MKK3/6 and MLK3 in livers of p38αLPC-KO 
           mice 
 
The phosphorylation of JNK is controlled by two upstream kinases, MKK7 and MKK4. MKK7 
was reported to specifically act on JNK and to be activated by TNF and environmental stress. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: LPS induced hyperactivation of MKK4, MKK3/6 and MLK3 in livers of p38αLPC-KO mice (A) 
Immunoblot analysis of the JNK-activating kinases MKK4 and MKK7 in the liver extracts from control and p38αLPC-
KO mice after LPS injection at the indicated time points. Tubulin acts as loading control. (B) Immunoblot analysis 
using an antibody detecting the phosphorylated forms of MKK3 and MKK6 (upper panel). (C) Immunoblot analysis 
using an antibody detecting the phosphorylated form of MLK3 (upper panel). Total MLK3 acts as loading control. 
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Assessment of MKK4 and MKK7 activation using immunoblot analysis with antibodies 
specifically recognizing their phosphorylated forms showed increased phosphorylation of 
MKK4, but not MKK7, in the liver of p38αLPC-KO mice compared with wild-type mice after LPS 
injection (Fig. 7 A). Further analysis showed increased phosphorylation of the p38α-
activating kinases MKK3/6 in livers from LPS-injected p38αLPC-KO mice (Fig. 7 B). Interestingly, 
MKK4 was reported to phosphorylate both JNK and p38 MAPK, and is normally not activated 
by TNF (Derijard, Raingeaud et al. 1995; Minden, Lin et al. 1995; Moriguchi, Toyoshima et al. 
1997; Tournier, Whitmarsh et al. 1999). Moreover the MAP3K MLK3 was found to be 
upregulated in livers from LPS-injected p38αLPC-KO mice (Fig. 7 C). 
 
3.2.7 p38α and IKK2 collaborate to prevent liver failure 
 
Despite massive JNK activation p38α-deficient livers are not sensitive to LPS/TNF challenge. 
This is most likely due to the NF-κB dependent transcriptional induction of anti-apoptotic 
genes such as c-FLIP (L) which seems to be sufficient to prevent TNF-induced apoptosis of 
hepatocytes lacking p38α. To test this hypothesis, p38αLPC-KO mice were additionally crossed 
with IKK2FL mice which alone are not sensitive to LPS/TNF-induced liver failure (Luedde, 
Assmus et al. 2005) (Luedde, Beraza et al. 2007). The efficient deletion of p38α and IKK2 in 
liver parenchymal cells was shown in Figure 8 A. p38α/IKK2LPC-KO mice were challenged with 
LPS and showed increased liver damage compared to single-mutant mice, shown by the 
analysis of serum alanine aminotransferase levels (Fig. 8 B). Measurement of apoptosis in 
the liver by TUNEL assay and by immunoblot analysis detecting caspase 3 cleavage 
confirmed these results and showed increased cell death in p38α/IKK2LPC-KO mice compared 
tp wild-type or p38α and IKK2 single-mutant mice at 10 h after LPS injection (Fig 8 C, D). In 
summary, these results indicate that p38α and IKK2 collaborate to protect the liver from 
LPS/TNF -induced toxicity. 
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Figure 8: p38α collaborates with IKK2 to protect the liver from LPS-induced toxicity. (A) Immunoblot 
analysis detecting the expression of IKK2 and p38α in the extracts of liver protein from control, p38αLPC-KO and 
p38α/IKK2LPC-KO mice. (B) Levels of free circulating ALT were measured in IKK2LPC-KO, p38α/IKK2LPC-KO and control 
mice before and 10 h after LPS injection. Mean values are depicted above each column. (C) Detection of 
apoptotic cells by TUNEL assay in liver sections from WT, IKK2LPC-KO and p38α/IKK2LPC-KO mice 10 h after LPS 
injection. (D) Immunoblot analysis of caspase 3 activation using antibodies that specifically detect total caspase 3 
(top panel) or the cleaved form of caspase 3 (middle panel) in liver extracts from mice with the indicated 
genotypes 10 h after LPS injection. NEMOLPC-KO mice were used as a positive control. Tubulin acts as loading 
control. 
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3.2.8 p38α/IKK2LPC-KO mice fail to resynthesize c-FLIP 
 
In order to confirm the inability of p38α/IKK2 negative hepatocytes to activate anti apoptotic 
NF-κB target genes, the levels of c-FLIP (L) were assessed in the liver of p38αLPC-KO, control 
and p38α/IKK2LPC-KO mice at various time points after i.p. injection with LPS.  
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Figure 9: (A-C) The levels of c-FLIP (L) were measured by immunoblot analysis in livers from WT, p38αLPC-KO and 
p38α/IKK2LPC-KO mice at the indicated time points after LPS injection using c-Flip (L) specific antibodies. Each lane 
represents an individual animal. 
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Immunoblot analysis showed reduced levels of c-FLIP (L) in p38α/IKK2LPC-KO double-mutant 
mice 10 h after LPS injection compared with single-mutant animals (Fig. 9 C), suggesting 
that controlling the levels of anti-apoptotic proteins such as c-FLIP (L) is one of the 
mechanisms through which p38α and IKK2 collaborate to protect the liver from LPS/TNF-
induced hepatocyte apoptosis (Fig. 10). 
 
The model: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: p38α collaborates with IKK2 to prevent liver failure in response to in vivo LPS/TNF challenge. 
TNF binding to TNFRI induces the activation of NF-κB and MAPK pathways, but can also induce cell death 
through the activation of caspase 8. Activation of NF-κB protects cells from TNF induced cell death by inducing 
the expression of anti-apoptotic proteins such as c-FLIP. Activation of JNK induces the E3 ubiquitin ligase ITCH to 
ubiquitinate c-FLIP, leading to its degradation. Lack of p38α in hepatocytes leads to hyperactivation of MKK3/6, 
MKK4 and JNK, upon in vivo LPS challenge. The increased sustained activation of JNK is not sufficient to induce 
cell death in the p38α deficient liver. When p38α ablation is combined with moderate inhibition of NF-κB, achieved 
by hepatocyte-restricted IKK2 ablation, in vivo LPS challenge results in increased degradation of c-FLIP and liver 
damage through caspase 8-mediated hepatocyte apoptosis. 
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3.3  The Role of liver p38α in chronic low grade inflammatory states. A model of 
             high fat diet induced obesity and insulin resistance. 
 
3.3.1 p38αLPC-KO mice do not gain more weight on a high fat diet compared to control  
            mice 
 
To test if liver p38α has a function in chronic low grade inflammatory states we applied a 
model of diet induced obesity and insulin resistance that is known to induce chronic low 
grade inflammatory states in various tissues. p38αLPC-KO and wild-type mice were fed a 
normal chow or a high fat diet (HFD) for 16 weeks. The weight of the mice was monitored on 
a weekly basis and the average weight of each group was calculated. Neither normal chow 
diet nor high fat diet induced differences in body weight between p38αLPC-KO and control mice 
(Fig. 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: p38αLPC-KO mice do not gain more weight on a high fat diet. (A) After weaning, the average 
bodyweight of p38αLPC-KO mice and wild-type mice fed chow or high fat diet was determined on a weekly basis for 
16 weeks of age (n=25). The average weight of each group was calculated. 
 
3.3.2 The deletion of p38α in liver parenchymal cell does not lead to an alteration in  
            blood glucose, serum insulin, cholesterol and triacylglyceride levels 
 
The liver is an important organ for glucose metabolism. It responds to insulin by inhibiting 
hepatic gluconeogenesis and increasing glycogen synthesis. Insulin resistant states lead to 
hyperglycemia and hyperinsulinemia. Therefore, blood glucose and insulin levels were 
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measured in p38αLPC-KO and wild-type mice after 16 weeks of chow or HFD, to assess the 
effect of a liver specific ablation of p38α on glucose (Fig. 12 A) and insulin levels (Fig. 12 B), 
which are indicators for the degree of insulin resistance. After HFD feeding, animals show 
hyperglycemia and hyperinsulinemia. Neverthelass, no differences were detected between 
p38αLPC-KO and wild-type animals. 
Moreover, the liver is the metabolic warehouse for lipids in the body. Thus, serum cholesterol 
(Figure 12 C) and triacyglyceride (Figure 12 D), were measured after 16 weeks of chow or 
HFD showing no significant differences between p38αLPC-KO and wild-type mice.  
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Figure 12: The deletion of p38α in liver parenchymal cell does not lead to an alteration in blood glucose 
and serum insulin levels (A) Blood glucose levels measured in p38αLPC-KO or control mice after 16 weeks of chow 
or HFD following an overnight fast. (B) Serum insulin levels from lean and obese p38αLPC-KO and control mice after 
an overnight fast. n=12  
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Figure 12: The deletion of p38α in liver parenchymal cell does not lead to an alteration in cholesterol and 
triacylglyceride levels. Cholesterol (C) and Triacylglyceride (D) levels in the serum of p38αLPC-KO and control 
mice, after 16 weeks of chow or HFD. n=12 
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3.3.3 Obese p38αLPC-KO mice are more insulin resistant than control mice 
 
The liver is a very important organ for glucose homeostasis and responds to insulin by down 
regulation of hepatic gluconeogenesis and increase of glycogen synthesis. Therefore, the 
regulation of glucose metabolism in p38αLPC-KO and wild-type mice was adressed by 
performing glucose (GTT) and insulin tolerance tests (ITT).  
 
p38αLPC-KO and wild-type mice that had been fed a chow or a HFD for 16 weeks were injected 
with 2g/kg bodyweight glucose into the peritoneal cavity. Blood glucose clearance was 
assessed 15, 30, 60 and 120 minutes after the injection. While lean p38αLPC-KO mice did not 
show an altered glucose clearance, compared to wild-type mice (Fig. 13 A), obese p38αLPC-
KO mice showed significantly impaired glucose clearance compared to the control animals 
(Fig 13 B).Thus, obese p38αLPC-KO mice less glucose tolerant than the wild-type animals. To 
test the response of these animals to insulin, an insulin tolerance test was performed. 0,75 
U/kg bodyweight of human regular insulin were injected into the peritoneal cavity of p38αLPC-
KO and wild-type mice that had been fed a chow or a HFD for 17 weeks. Figure 13 D shows 
that obese p38αLPC-KO mice responded much less to the injection of insulin since they showed 
only a mild decrease in blood glucose levels after insulin injection while the response in wild 
type animals is significantly stronger. The difference in response to the injected insulin 
indicates, that obese p38αLPC-KO mice are more insulin resistant than control mice (Fig. 13 D). 
Lean p38αLPC-KO mice did not show any alterations in insulin sensitivity compared to control 
mice (Fig. 13 C). In summary, these results clearly indicate that hepatocyte-specific deletion 
of p38α in obese mice increases insulin resistance. 
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Figure 13: p38αLPC-KO mice are more insulin resistant than control mice:  (A) Glucose tolerance tests were 
performed with lean p38αLPC-KO and control mice at 21 weeks of age. (B) Glucose tolerance tests of mice with the 
indicated genotypes were performed at 21 weeks of age after 16 weeks of HFD feeding (n=21). Values are mean 
± SEM. (Error bars < 1, not visible) 
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Figure 13: p38αLPC-KO mice are more insulin resistant than control mice  (C) Insulin tolerance tests of p38αLPC-
KO  and control mice were performed at 22 weeks of age after 17 weeks of chow diet feeding. (D) Insulin tolerance 
tests of mice with the indicated genotypes were performed at 22 weeks of age after 17 weeks of HFD feeding. 
(n=21) Values are mean ± SEM. (Error bars < 1, not visible) 
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3.3.4 p38α deficient livers show decreased insulin stimulated signaling 
 
In order to assess insulin mediated signaling in the peripheral organs, obese p38αLPC-KO and 
wild-type mice were anesthetized and injected with insulin through the vena cava.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 p38α deficient livers show decreased insulin stimulated signaling: p38αLPC-KO mice and control 
mice that were fed a HFD for 18 weeks were anesthetized and injected with insulin through the vena cava. 2 and 
5 minutes after the injection livers and muscle were harvested respectively. Insulin signaling in liver (A) and 
muscle (B) was assessed by immunoblot analysis unsing pASK and pGSK3α/β specific antibodies. Actin/Tubulin 
serve as loading control. 
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2 minutes after the injection of insulin the livers were harvested. Muscle was taken 5 minutes 
after the injection of insulin. Insulin stimulated signal transduction was measured in these 
organs by immunoblot analysis assessing the phosphorylation status of downstream insulin 
receptor molecules AKT and GSK3. While insulin stimulated signaling was impaired in the 
livers of p38αLPC-KO mice (Fig. 14 A), insulin signaling in muscle taken from p38αLPC-KO mice was 
not affected (Fig. 14 B). Thus, the liver specific knockout of p38α results in local insulin 
resistance in the liver but not in other peripheral organs like the muscle. 
 
3.3.5 p38α deficient primary hepatocytes show decreased insulin stimulated 
            signaling 
 
Next, the insulin stimulated signaling in primary isolated hepatocytes was assessed. p38αLPC-
KO mice and control mice were perfused with collagenase solution to obtain primary 
hepatocytes. After an overnight culture, control and p38α-/- hepatocytes were stimulated with 
200mM insulin at the indicated time points. Immunoblot analysis of the downstream insulin 
receptor signaling molecule AKT revealed a clear impairment of insulin stimulated signaling 
in p38α-/- hepatocytes (Fig. 15 A). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: p38α deficient primary hepatocytes show decreased insulin stimulated signaling: Primary 
isolated hepatocytes were stimulated with 200nM insulin for the indicated times. Assessment of downstream 
receptor insulin signaling was performed by immunoblot using pAKT specific antibodies. Actin serves as  loading 
control. 
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The experiments in Figures 14 and 15 unequivocally demonstrate that a deletion of p38α in 
liver parenchymal cells leads to an impairment of insulin signaling in vivo and in vitro. 
Nevertheless, the insulin resistance induced by the knockout of p38α seems to be restricted 
to the liver, since muscle of p38αLPC-KO mice shows normal insulin stimulated signaling. 
 
3.3.6 Liver parenchymal cell specific knockout of p38α does not alter the liver lipid  
            content 
 
Impaired insulin signaling can be induced by various mechanisms. Among these causative 
machanisms are changes in the liver lipid content. In particular diacylglycerides (DAGs) and 
ceramides have been implicated in the negative regulation of insulin signaling. According to 
this theory, obesity results in an increased flux of free fatty acids into the circulation and 
uptake by hepatocytes. Activated fatty acids (i.e., fatty acyl-CoAs) are metabolized primarily 
via oxidation or storage. When fatty acid flux exceeds the ability of these pathways to 
dispose of fatty acyl-CoAs, intermediates of fatty acid metabolism (e.g., DAG, PA, LPA, 
ceramide) accumulate. As a result, these fatty acid intermediates can activate a number of 
different serine kinases that negatively regulate insulin action. Ceramide has also been 
shown to impair insulin action, although the precise mechanisms leading to insulin resistance 
are, to date, unknown (Summers 2006).  
In order to investigate a possible shift in lipid liver content which might be causal to the 
impaired insulin signaling in p38α deficient livers and hepatocytes, liver sections were 
analyzed. H&E and oil red O stainings were performed. H&E staining did not show 
alterations in liver histology between p38α deficient and wild-type livers (Fig. 16 A). Also the 
lipid content did not seem to vary indicated between p38α deficient and wild-type livers as 
indicated by the oil red O staining (Fig. 16 B). 
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Figure16: The liver parenchymal knockout of p38α does not alter the liver lipid content: (A) Representative 
pictures of Haematoxylen and Eosin staining on liver sections, taken from normal chow or HFD diet treated 
p38αLPC-KO or wild-type mice. (B) Liver lipid content in p38αLPC-KO or wild-type mice after chow or HFD stained by oil 
red O. 
A qualitative lipid analysis of different lipid subclasses by thin layer chromatography was 
performed to reveal a possible alteration in different lipid classes between p38α deficient and 
wild-type livers. Nevertheless, after 18 weeks chow or HFD feeding the amounts of 
triacylglycerides, cholesterol esters, 1,2 DAGs, 1,3 DAGs and free fatty acids did not show 
significant differences (Fig. 16 C and D). Therefore, a change in lipid quantity and quality can 
be ruled out as a causative factor for the impaired insulin signaling in p38α deficient livers 
and hepatocytes. 
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Figure 16: Unaltered liver lipid content in p38α deficient livers:  (A) Assessment of triacylglycerides, (B) 
cholesterol esters, 1,2 DAGs, 1,3 DAGs and free fatty acids by thin layer chromatography from p38α or control 
livers after 18 weeks of HFD. n=12 
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3.3.7 The deletion of p38α in liver parenchymal cells does not alter the expression of  
            TNF, IL-6 and IL1-β in liver  
 
Increased expression of inflammatory cytokines has been reported to be a cause for the 
development of insulin resistance (Hotamisligil 2006). In order to assess the expression 
levels of inflammatory cytokines in the liver, quantitative PCR was performed on cDNA 
isolated from p38α deficient and wild-type livers taken from mice that received chow or HFD 
for 18 weeks.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Unaltered expression of inflammatory cytokines in liver. Quantitative PCR performed on RNA 
isolated from p38α deficient and control livers, taken from mice that were fed a chow or a high fat diet. Expression 
levels of (A) TNF, (B) expression levels of IL-1β. n=5 
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Figure 17: Unaltered expression of inflammatory cytokines in liver. Quantitative PCR performed on RNA 
isolated from p38α deficient and control livers taken from mice that were fed a chow or a high fat diet. (C) 
Expression levels of IL-6. n=5 
 
TNF, IL1-β and IL-6 are key cytokines that have been reported to induce insulin resistance in 
various organs (Hotamisligil 2006). Nevertheless, p38α deficient livers did not show an 
altered expression of TNF, IL-6 and IL-1β (Fig. 17 A-C). This suggests that the increase in 
insulin resistance in obese p38αLPC-KO mice is not caused by an increased expression of 
inflammatory cytokines in the liver. 
 
3.3.8 Unaltered expression of inflammatory cytokines in adipose tissue taken from 
            p38αLPC-KO and control mice. 
 
Independently from the unaltered cytokine expression in the liver, factors that are released 
by the liver could lead to a change in cytokine production in other tissues like the adipose 
tissue. Therefore, the expression profile of inflammatory cytokines in the adipose tissue was 
investigated. Similar to the liver, there were no changes in the expression of TNF (Fig. 18 A), 
IL-6 (Fig. 18 B), IL-1 β (Fig. 18 C) and MCP-1 (Fig. 18 D) between tissues taken from 
p38αLPC-KO mice and wild-type mice. Nevertheless, there was a 3 fold elevation in expression 
of TNF in response to the HFD treatment in tissues taken from p38αLPC-KO mice and control 
mice (Fig. 18 A).  
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Fig 17: Unaltered expression of inflammatory cytokines in the adipose tissue. Quantitative PCR performed 
on RNA isolated from adipose tissue isolated from p38αLPC-KO and control mice that were fed a chow or a high fat 
diet. (A) Expression levels of TNF, (B) IL6, and IL1-b. 
 
 
 
 
 
 
 
 
Figure 18: Unaltered expression of inflammatory cytokines in the adipose tissue. Quantitative PCR 
performed on RNA isolated from adipose tissue isolated from p38αLPC-KO and control mice that were fed a chow or 
a high fat diet. Expression levels of (A) TNF, (B) IL6, and (C) IL1-β.n=5 
 
 
 
 
 
 
A 
 
B 
 
C 
TNF 
IL-6 
IL1-β
Results
 
81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Unaltered expression of inflammatory cytokines in the adipose tissue. Quantitative PCR 
performed on RNA isolated from adipose tissue isolated from p38αLPC-KO and control mice that were fed a chow or 
a high fat diet. Expression levels of (D) MCP-1. 
 
3.3.9 Increased activation of JNK in the livers of obese p38αLPC-KO mice 
 
In the LPS/TNF induced liver toxicity model it became apparent that p38α deficient 
hepatocytes show hyperactivated JNK in response to TNF (Heinrichsdorff, Luedde et al. 
2008). Therefore, the activation of JNK in livers taken from p38αLPC-KO mice and control mice 
that were fed a HFD for 18 weeks was assessed. Consistent with the data from the acute 
liver toxicity model, livers taken from obese p38αLPC-KO mice had a higher activation of JNK 
than livers taken from wild-type mice (Fig. 19 A).  
Hyperactivation of JNK has been shown in various models of obesity and insulin resistance 
where it was reported to have an inhibitory effect on insulin signaling. According to these 
models, JNK is able to interact with and phosphorylate the insulin receptor substrate 1 (IRS1) 
at a negatively regulatory serine position (Hirosumi, Tuncman et al. 2002; Solinas, Naugler et 
al. 2006; Solinas, Vilcu et al. 2007).  
In addition to livers taken from HFD treated p38αLPC-KO mice, isolated resting primary 
hepatocytes were tested for JNK activity. Elevated levels of JNK activity were detected 
independent from a stimulus (Fig. 19 B), suggesting that the p38α knockout results in 
intrinsic JNK hyperactivation. 
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Figure 19: Hyperactivation of JNK in p38αLPC-KO livers and primary hepatocytes. (A) Livers taken from obese 
p38αLPC-KO and control mice were tested for JNK activity by immunoblot. Phospho-specific JNK antibodies were 
used to detect JNK activity. (B) Primary p38α deficient and control hepatocytes were tested for JNK activity using 
immunoblot analysis. Phospho-speciffic JNK antibodies were used to detect JNK activity. Tubulin serves as a 
loading control. 
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3.3.10  Inhibition of JNK can only partially restore insulin signaling in p38α deficient 
             hepatocytes 
 
JNK inhibitors are commonly used in vitro to impair JNK signaling and have been discussed 
as a potential therapeutic for various diseases including insulin resistance and type 2 
diabetes. We stimulated primary p38α deficient and control hepatocytes with insulin in the 
presence or absence of the JNK inhibitor VII. Even though the activity of JNK was effectively 
reduced in the presence of the inhibitor, which is indicated by the decrease in 
phosphorylation of the JNK substrate c-Jun, insulin signaling indicated by AKT 
phosphorylation, was only mildly restored (Fig. 20).This result indicates that JNK 
hyperactivation might not be the only causative mechanism that leads to the impairment of 
insulin signaling in p38α deficient cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Inhibition of JNK can only partially restore insulin signaling in p38α deficient hepatocytes. 
p38α and control hepatocytes were stimulated with 200nM insulin in the presence or absence of 10nM JNK 
inhibitor. Insulin induced signaling was assessed by immunolot analysis using phospho-AKT specific antibodies. 
The effect of the JNK inhibition was tested using phosphor-c-Jun specific antibodies. Actin serves as a loading 
control. 
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3.3.11 Increased phosphorylation of Ser307 in p38α deficient hepatocytes 
 
One of the molecular mechanisms that were shown to impair insulin signaling is the 
phosphorylation of the insulin receptor substrate (IRS) at negative regulatory serine positions 
that impair the interaction with the insulin receptor substrate and the next molecule in the 
insulin signaling pathway, the PI3 kinases. Various serine/threonine kinases have been 
implicated in the negative regulatory phosphorylation of the insulin receptor substrate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: p38α deficient hepatocytes show increased phosphorylation of IRS1 at serine 307. Primary 
isolated p38α defecient and control hepatocytes were stimulated with TNF for 1 hour. Immunoblot analysis was 
performed to assess the phosphorylation of IRS1 at serine 307. Actin serves as a loading control. 
 
Phosphorylation of the insulin receptor substrate at a negative regulatory serine position 307 
was tested in p38α and wild-type hepatocytes that were stimulated with TNF for 1 hour, in 
the presence or absence of a JNK inhibitor. Immunoblot analysis showed that p38α deficient 
hepatocytes have increased serine 307 phosphorylation of the IRS1, before and after 
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stimulation with TNF. Interestingly, the presence of a JNK inhibitor did not impair this degree 
of phosphorylation suggesting that other kinases are also involved in the phosphorylation of 
the IRS1. Furthermore, the activation of upstream JNK kinases MKK4, which is an MAP2K, 
as well as that of ASK and TAK1, which are MAP3Ks was tested (Fig. 21). Surprisingly, 
immunoblot analysis showed that several upstream kinases of JNK including MKK4, ASK1 
and TAK1 are hyperphosphorylated in p38α deficient hepatocytes, independent from TNF 
stimulation. 
 
3.3.12 p38α negatively regulates JNK and upstream kinases through an unknown  
           mechanism and therefore positively regulates insulin signaling 
 
In summary p38α seems to control the activation status of various serine/threonine kinases 
involved in JNK signaling. Besides hyperativated JNK, MKK4, TAK1 and ASK1 are also 
hyperactivated in p38α deficient cells. Together, these kinases might lead to a 
phosphorylation of the IRS at Serine 307 which prevents the transduction of the insulin 
signal. As a result, hepatic gluconeogenesis is not inhibited by an insulin stimulus and 
glycogen synthesis is not increased. 
 
The model: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 22: p38α negatively regulates JNK and upstream kinases through an unknown mechanism and 
therefore positively regulates insulin signaling. 
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4. Discussion 
 
The role of liver p38α in acute and chronic inflammatory reactions 
p38α has been identified as an important player in inflammatory reactions in numerous 
studies (Guan, Buckman et al. 1998; Johnson and Bailey 2003; Hollenbach, Neumann et al. 
2004). As the central part of this thesis the function of p38α in acute and chronic 
inflammatory conditions in the liver was examined. In order to do this, a conditional mouse 
model was utilized taking advantage of the Cre-loxP recombination system to generate a 
liver parenchymal specific knockout of p38α (Heinrichsdorff, Luedde et al. 2008). 
 
4.1 The role of liver p38α in acute inflammatory reactions 
4.1.1 Despite hyperactivation of JNK, p38αLPC-KO mice are not sensitive to LPS-induced 
            liver failure 
 
Acute liver damage can be caused by a wide range of stimuli. TNF has been shown to play 
an outstanding role during the development of liver failure and is known to activate MAP 
kinases including p38α. In order to find new targets for medical intervention in cases of acute 
liver failure, it is important to gain more knowledge about the molecular events that precede 
this severe medical condition. LPS is one of the most potent TNF inducers but usually does 
not cause hepatocyte apoptosis unless it is co-administered with D-Galactasoamine (GalN) 
which specifically blocks gene transcription in the liver (Decker and Keppler 1974; Bradham, 
Plumpe et al. 1998). The aim of the first part of this thesis was to analyze the LPS/TNF 
induced apoptotic signals in mice specifically lacking p38α in liver parenchymal cells. To 
study the role of p38α in acute inflammatory liver conditions in a more physiological context 
we did not co-administere GalN with the LPS. 
Upon LPS injection, deletion of p38α in liver parenchymal cells does not sensitive mice to 
hepatocyte apoptosis (Fig. 2). This result was somewhat surprising since the injection of LPS 
caused massive hyperactivation of JNK in the livers of these mice (Fig 3 A). In various 
studies JNK has been described to have a proapoptotic role (Davis 2000; Weston and Davis 
2002). In the liver, it was shown that LPS injection causes hepatocyte apoptosis through the 
proteasomal degradation of c-FLIP (L) when anitapoptotic signals are inhibited through the 
injection of GalN. (Chang, Kamata et al. 2006). Furthermore, upon liver parenchymal cell 
specific deletion of NEMO, which prevents canonical NF-κB signaling in hepatocytes, LPS 
injection caused massive liver apoptosis. Interestingly, after injection of LPS, the activation of 
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JNK seems to be weaker in NEMO LPC-KO livers than in p38αLPC-KO livers (Fig. 3 A, B). (Luedde, 
Beraza et al. 2007). Compared to control mice the activation of JNK in NEMO LPC-KO livers is 
moderately prolonged (Fig. 3 B). These results indicate that p38α negatively regulates JNK. 
In livers that have intact NF-κB signaling, hyperactivation of JNK is not sufficient to induce 
hepatocyte death. Conversely, abolishment of NF-κB signaling in the NEMOLPC-KO mice 
hypersensitizes hepatocytes to LPS/TNF induced cell death, without leading to elevated 
levels of JNK. Thus, in a model of LPS/TNF induced liver toxcicty, NF-κB signaling seems to 
play an important role in suppressing a proapoptotic stimulus executed by JNK, leading to 
the survival of hepatocytes. Mechanistically, NF-κB signaling seems to be responsible for the 
expression of various antiapoptotic genes including c-FLIP, which competes with FADD for 
the binding to procaspase 8 and therefore inhibits the apoptotic potential of the TNF receptor 
complex II (Micheau, Lens et al. 2001; Chang, Kamata et al. 2006). Immunoblot analysis 
performed on livers taken from p38αLPC-KO, NEMOLPC-KO and control mice after LPS injection, 
indicated a slight decrease of c-FLIP (L) protein levels 4 h after LPS injection (Fig. 5 A). 
However, 10 h after LPS injection, the levels of c-FLIP (L) were similar in p38αLPC-KO and 
control mice (Fig. 2 A). By contrast, the levels of c-FLIP (L) were diminished in NEMO 
deficient livers 10 h after LPS injection (Fig. 5 A, lanes 7–9), which is consistent with the 
increased hepatocyte apoptosis detected at this point. These results indicate that even a 
massive activation of JNK is not sufficient to reduce intracellular levels of c-FLIP (L) below 
the threshold required to sensitize hepatocytes to LPS/TNF-induced death, while even a 
moderate prolongation of JNK activity results in degradation of c-FLIP (L) and apoptosis of 
hepatocytes with abolished NF-κB signaling. 
 
4.1.2 Oxidative stress and MAP kinase phosphatases are not involved in the 
            hyperactivation of JNK in p38α deficient livers.  
 
There is accumulating evidence that p38α generally suppresses JNK activity independent of 
cell type. Besides the finding that JNK is hyperactivated in p38α defecient hepatocytes, it 
was also shown in other cell types that JNK is negatively regulated by p38α (Hui, Bakiri et al. 
2007; Perdiguero, Ruiz-Bonilla et al. 2007; Sakurai, He et al. 2008). 
Several reasons could account for the hyperactivation of JNK in p38α deficient hepatocytes: 
Elevated oxidative stress could be the culprit leading to the hyperactivation of JNK in the 
absence of p38α (Kamata, Honda et al. 2005). In order to test this hypothesis, animals were 
fed the antioxidant compound butylated hydroxyanisole (BHA) for 48 hours, before the 
injection of LPS. Nevertheless, despite treatment with BHA, p38α deficient livers still showed 
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hyperactivation of JNK after LPS injection ruling out oxidative stress as a causative 
mechanism for JNK hyperactivation in p38α deficient livers (Fig. 6 A). 
The p38 pathway also regulates the activity of various transcription factors (Hazzalin, Cano 
et al. 1996; Wang and Ron 1996; Han, Jiang et al. 1997; Janknecht and Hunter 1997; 
Whitmarsh, Yang et al. 1997; Huang, Ma et al. 1999; Zhao, New et al. 1999; Yee, Paulson et 
al. 2004). Thus, p38α might be involved in the expression of phosphatases controling JNK 
activity. To test this hypothesis, protein levels of various MAP kinase phosphatases were 
assessed. MKP1, MKP2 and MKP3 that are known to be involved in the regulation of JNK 
activity (Keyse 2008) and were shown to dephosphorylate MAP kinases at both 
phosphorylation sites, the Thr and Tyr residue in the activation loop effectively abrogating the 
activity of MAP kinases. Therefore, they are called dual specifity phosphatases (DUSPs) 
(Liu, Shepherd et al. 2007). Furthermore, protein levels of pp5 (Golden, Swingle et al. 2008), 
pp1me pp1a and pp2a (Junttila, Li et al. 2008) were examined, which are phosphatases 
generally involved in cellular stress responses. As shown in Figure 6, none of the potential 
phosphatases regulating JNK showed altered expression in p38α deficient livers ruling out 
the possibility that altered protein levels of JNK phosphatases are involved in the 
hyperactivation of JNK (Fig. 6 B and C). In addition to transcriptional regulation, MKPs can 
also be regulated by and protein stabilization and phosporytation which inceases catalytic 
activity. This study does not rule out that the possibility that p38 is involved in 
phosphorylation of MKPs or stabilization of MKP transcripts. Therefore, a possible effect of 
p38α on the activity of phosphatases has to be studied in further detail. 
 
In addition, upstream kinases of JNK are also hyperactivated in the livers of p38αLPC-KO mice 
upon LPS injection. The phosphorylation of JNK is controlled by two upstream kinases, MAP 
kinase kinase (MKK) 7 and 4. MKK7 was reported to specifically activate JNK and seems to 
be activated by TNF and environmental stress (Hui, Bakiri et al. 2007). Surprisingly, 
immunoblot analysis showed increased phosphorylation of MKK4, but not MKK7, in the liver 
of p38αLPC-KO mice compared to wild-type livers, after LPS injection (Fig. 7 A). Furthermore, 
increased phosphorylation levels of the p38α activating kinases MKK3/6 in the livers of LPS-
injected p38αLPC-KO mice were found (Fig. 7 B). The finding that MKK4 is hyperactivated in 
livers of p38αLPC-KO mice after LPS injection is surprising, since it was reported to 
phosphorylate both JNK and p38 MAPK, but has never been shown to be activated by TNF. 
(Derijard, Raingeaud et al. 1995; Minden, Lin et al. 1995; Moriguchi, Toyoshima et al. 1997; 
Tournier, Whitmarsh et al. 1999). Therefore, in the liver MKK4 can also be accounted as a 
kinase that is able to activate JNK, in response to TNF. The fact that hyperactivation of 
MKK7, a well accepted MAP2K in TNF signaling, was not detected might be due to the lack 
of a good commercial antibody to detect the phosphorylated form of MKK7. There are also 
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indications that upstream kinases of MKK4, including MLK3, are hyperactivated in the livers 
of p38αLPC-KO mice after LPS injection. (Fig. 7 C).  
 
Taken together these results suggest that neither oxidative stress nor JNK phosphatases 
seem to regulate the hyperactivation of JNK. On the other hand, the hyperactivation of the 
upstream kinases MKK4, MKK3/6 as well as the MAP3K MLK3 suggest a defect more 
proximal to the TNFR I. One possible explanation that has not been investigated thus far 
could be an influence of p38α on the scaffolding of adaptor proteins like JIP, where JNK and 
also MKKs scaffold to increase specificity and intensity of the signal (Yasuda, Whitmarsh et 
al. 1999; Chang and Karin 2001). Furthermore, a defect in negative regulation of signal 
transduction at the receptor which seems to rely on the dissociation of a multiprotein 
signaling complex controlled by the ubiquitin mediated degradation of TRAF3 (Matsuzawa, 
Tseng et al. 2008; Karin and Gallagher 2009) could be causal for hyperactivation of JNK. 
Even though this mechanism is mainly described for the TNFR family member CD40, there is 
evidence that it may also apply to the TNFR itself (Matsuzawa, Tseng et al. 2008). The 
possibility that p38α might have a regulatory function in this complex mechanism, has to be 
investigated in further detail. 
4.1.3 p38α and IKK2 collaborate to prevent LPS/TNF induced liver failure 
 
Despite massive hyperactivation of JNK, p38αLPC-KO livers are not sensitized to endotoxin 
induced cell death. Thus, it is quite likely that survival pathways keep hepatocytes in a state 
that does not allow the induction of apoptosis. To this end, the NF-κB signaling pathway 
seems to play an important role. Hepatocytes deficient for canonical NF-κB signaling are 
hypersensitive to LPS/TNF induced apoptosis (Fig. 2 B and C) (Luedde, Beraza et al. 2007). 
Partial inhibition of NF-κB signaling through deletion of IKK2 is not sufficient to induce 
hepatocyte death upon in vivo LPS injection (Fig. 8 A) (Luedde, Heinrichsdorff et al. 2008). 
Nevertheless, it was hypothesized that partial inhibition of NF-κB together with 
hyperactivation of proapoptotic JNK signaling should sensitize p38α/IKK2 deficient 
hepatocytes towards LPS/TNF induced cell death. Indeed, elevated serum transaminases, 
TUNEL staining and caspase 3 cleavage after LPS injection show that p38α/IKK2LPC-KO mice 
are sensitized to LPS/TNF induced hepatocyte death. Thus, in a model of LPS/TNF induced 
liver toxicity, partial impairment of NF-κB signaling, in concert with hyperactivation of JNK, 
seems to bring hepatocytes into a state that allows the induction of apoptosis. This 
experiment highlights the fine balance between hepatocyte survival and death that is mainly 
influenced by the balance of pathways that are activated downstream of TNFR I namely NF-
κB, JNK and p38α.  
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In order to dissect the molecular mechanisms that are responsible for the sensitization of 
p38α/IKK2LPC-KO mice towards LPS/TNF induced hepatocyte death, anti-apoptotic target genes 
induced by NF-κB were examined. NF-κB can promote the expression of several 
antiapoptotic genes such as TRAF1, TRAF2, cIAP-1, c-IAP-2, and c-FLIP (Wang, Mayo et al. 
1998). One of the NF-κB target genes that is involved in the prevention of TNF induced 
apoptosis is c-FLIP (Wang, Mayo et al. 1998; Kreuz, Siegmund et al. 2001; Micheau, Lens et 
al. 2001). The short form of c-FLIP, c-FLIP (s), contains two death effector domains and is 
structurally related to the viral FLIP inhibitors of apoptosis, whereas the long form, c-FLIP (L), 
contains an additional caspase-like domain, in which the active-centre cysteine residue is 
substituted by a tyrosine residue. c-FLIP (s) and c-FLIP (L) interact with the adaptor protein 
FADD and the protease FLICE and potently inhibit apoptosis induced by all known human 
death receptors, including TNFR I (Irmler, Thome et al. 1997). It has also been shown that c-
FLIP (L) plays a crutial role in JNK mediated cell death, since TNF mediated JNK activation 
accelerates turnover of the NF-κB induced antiapoptotic protein c-FLIP by phosphorylation 
and activation of the E3 ubiquitin ligase Itch. This in turn specifically ubiquitinates c-FLIP and 
induces its proteasomal degradation (Chang, Kamata et al. 2006) 
 
Figure 6 clearly shows that c-FLIP (L) levels decrease in the livers of p38αLPC-KO mice, 4 hours 
after the injection of LPS. 10 hours after the injection of LPS, c-FLIP (L) protein is 
resythesized preventing induction of death receptor mediated apoptosis. In contrast to this, 
after LPS injection, p38α/IKK2 deficient livers fail to resynthesize c-FLIP (L). c-FLIP levels 
remain below the threshold, allowing hepatocyte apoptosis to take place. Thus, the balance 
between JNK and NF-κB activation plays a crucial role deciding over hepatocyte survival and 
death in LPS/TNF challenged livers that show acute inflammatory reactions. The NF-κB 
target gene c-FLIP, which can be degraded through JNK by the activation of the E3 ubiquitin 
ligase ITCH seems to play a crucial role protecting the liver from massive hepatocyte death, 
in states where JNK activation is high. Therefore, p38α and IKK2 collaborate to prevent liver 
failure.  
 
In conclusion, these results have important implications for our understanding of the 
mechanisms regulating TNF responses in the liver. Although JNK activation facilitates TNF-
induced apoptosis in NF-κB deficient liver cells, the results show that even excessive JNK 
activity is not sufficient to sensitize hepatocytes with intact NF-κB signaling to TNF toxicity. 
However, when p38α deficiency is combined with the ablation of IKK2, lack of negative JNK 
regulation synergizes with the partial impairment of NF-κB activity, to sensitize the liver to 
endotoxin-induced failure (Fig. 10). 
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4.2 The role of liver p38α in chronic low grade inflammatory states. A model of 
            high fat diet induced obesity and insulin resistance. 
 
Obesity, insulin resistance and type 2 diabetes are closely associated with chronic 
inflammation that involves abnormal cytokine production, the increase of acute-phase 
reactants and activation of a network of inflammatory signaling pathways (Wellen and 
Hotamisligil 2005). The combinatorial and additive action of different signaling pathways in 
metabolic homeostasis is a crucial but poorly addressed subject. In order to understand the 
contribution of inflammatory pathways that are downstream of TNF receptor signaling it is 
important to investigate their contribution in peripheral organs like the liver, muscle and 
adipose tissue. The liver is an important contributor to the normal regulation of glucose 
homeostasis. The ability of insulin to inhibit hepatic gluconeogenesis is an important aspect 
of insulin-stimulated clearance of blood glucose. The liver is therefore a potential site of 
metabolic regulation that influences insulin resistance. In the liver, pathways like JNK and 
NF-κB signaling were investigated intensively in chronic subacute inflammatory states 
induced by obesity showing that both molecules have a negative effect on insulin signaling 
(Hirosumi, Tuncman et al. 2002; Arkan, Hevener et al. 2005; Cai, Yuan et al. 2005). The p38 
signaling pathway has not been investigated for its contribution to low grade inflammatory 
states in the liver induced by obesity. Therefore, in the second part of this thesis the effect of 
a liver specific deletion of p38α in a high fat diet induced model of obesity and insulin 
resistance was investigated. 
 
4.2.1         p38αLPC-KO are more insulin resistant than control mice 
 
p38αLPC-KO that were placed on HFD for 16 weeks, did not gain more weight on a HFD than 
control mice. Therefore, we concluded that the liver parenchymal knockout of p38α did not 
alter energy homeostasis (Fig. 11). Moreover, the liver parenchymal knockout of p38α did not 
cause any differences in blood glucose levels indicating that the metabolic phenotype of 
these mice is rather mild (Fig. 12 A). Similar to blood glucose levels, serum insulin levels 
were higher in HFD treated animals compared to animals that received chow diet, indicating 
a higher degree of insulin resistance. Interestingly, after chow diet there was a trend towards 
higher levels in p38αLPC-KO mice, suggesting that these mice may need to secrete more insulin 
to maintain normal glucose levels in order to compensate for a potential metabolic 
dysfunction in the liver. In an insulin resistant state, after HFD, where insulin levels are 
generally higher, this trend was not observed (Fig. 12 A). Furthermore, no differences in 
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serum triacylglyeride and cholesterol levels were observed, indicating that the secretion of 
lipids was not altered in mice deficient for p38α in liver parenchymal cells (Fig. 12 C, D). 
In the glucose tolerance tests obese p38αLPC-KO mice failed to clear the injected glucose as 
efficient as control mice (Fig. 13 A). The insulin tolerance test showed a significantly impaired 
response to insulin in obese p38αLPC-KO mice (Fig. 13 B). Thus, obese p38αLPC-KO mice are more 
insulin resistant than control mice. Increased amounts of hepatic gluconeogenesis are likely 
to be responsible for this phenotype. Unfortunately, clamp studies to determine the hepatic 
glucose production and disposal of glucose in the peripheral tissues could not be realized in 
this study. In vivo insulin injections, investigating the response of the different peripheral 
organs to insulin, indicated a local insulin resistance in the liver caused by the deletion of 
p38α, while the muscle was not affected (Fig. 14 A, B). Moreover, p38α deficient primary 
hepatocytes stimulated with insulin showed clearly impaired insulin mediated signaling (Fig. 
15). Thus, the deletion of p38α in hepatocytes leads to an impairment of insulin signaling and 
is responsible for the increased insulin resistance in obese p38αLPC-KO mice.  
4.2.2         Lipids and the expression of inflammatory cytokines do not contribute to the 
                 development of insulin resistance 
 
Local insulin resistance can be caused by several mechanisms. One of them is the 
accumulation of toxic lipid intermediates like diacylglycerols (DAGs) but also storage lipids 
like triacylglycerols (Samuel, Liu et al. 2004; Neschen, Morino et al. 2005; Zhang, Liu et al. 
2007). DAGs accumulate in skeletal muscle and liver when the rate of fatty acid delivery to 
these tissues exceeds the rate of intracellular fat oxidation and/or conversion to neutral lipids. 
Increased intracellular DAG levels lead to activation of PKC-θ and PKC-ε in skeletal muscle 
and liver, respectively, which in turn, decreases insulin-stimulated IRS-1/IRS-2 tyrosine 
phosphorylation, PI3K activation and downstream insulin signaling. To test if a dysregulation 
in liver lipids contributes to the elevated insulin resistance, liver lipid quantity and quality of 
p38αLPC-KO mice was compared to control mice. Histology and thin layer chromatography of 
livers did not show any differences in liver lipid quality and quantity. Thus, impaired insulin 
signaling in the livers of p38αLPC-KO mice does not seem to be caused by a difference in lipid 
content, a factor known to impair insulin signaling (Fig. 16 A, B, C, D).  
Furthermore, the expression of inflammatory cytokines in the livers of p38αLPC-KO mice was 
assesed. Elevated expression of inflammatory cytokines by resident and infiltrating immune 
cells or by hepatocytes themselves can potentially lead to an increase of insulin resistance 
(Hotamisligil 2006). Hepatocyte specific deletion of IKK2 was shown to protect mice from diet 
induced insulin resistance due to a decreased expression of inflammatory cytokines in the 
liver (Arkan, Hevener et al. 2005). Therefore, an elevated expression of inflammatory 
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cytokines in p38α deficient livers could potentially cause a local insulin resistance through the 
activation of inflammatory signaling pathways. Quantitative analysis of cytokine expression in 
the livers of p38αLPC-KO mice did not reveal any significant differences in TNF, IL-1-β or IL-6 
expression (Fig. 17). TNF, IL-1β or IL-6 are heavily implicated in causing insulin resistance 
through impairment of insulin signaling (Hotamisligil 1999; Larsen, Faulenbach et al. 2007; 
Sabio, Das et al. 2008). Conclusively, we did not find any indication that an altered liver 
expression of TNF, IL-1-β or IL-6 might be the cause for decreased insulin signaling in p38α 
deficient livers. 
 
4.2.3        Increased activation of JNK in the livers of p38αLPC-KO mice 
 
During the biochemical characterization of p38α deficient livers taken from obese mice a 
significant hyperactivation of JNK was detected (Fig. 19 A). In agreement with the LPS/TNF 
induced model of acute liver inflammation, liver p38α also negatively regulates JNK in 
chronic low grade inflammatory states. It is also noteworthy that this hyperactivation of JNK 
was also observed in resting primary hepatocytes. Therefore, p38α-/- cells have elevated 
intrinsic JNK activity regardless of the stimulus (Fig. 19 B).  
JNK has been implicated as a negative regulator of insulin signaling in various studies.  
JNK1-/- mice were shown to be protected from diet induced obesity and insulin resistance 
(Hirosumi, Tuncman et al. 2002). Also, an interaction between JNK1 and the insulin receptor 
substrate was shown, leading to its negative regulatory phosphorylation (Solinas, Naugler et 
al. 2006) Nevertheless, new data generated with conditional JNK1 knockout mice puts 
previous publications generated with JNK1-/- mice into a different light. The protection of  
JNK1-/- mice against diet induced obesity seems to be caused by a reduced somatic growth 
in the presence of reduced circulating growth hormone (GH) and insulin-like growth factor 1 
(IGF1) concentrations, as well as increased thyroid axis activity (Belgardt, Mauer et al.). 
There is controversial data about the involvement of JNK1 in the hematopoetic compartment 
(Solinas, Vilcu et al. 2007; Sabio, Das et al. 2008; Vallerie, Furuhashi et al. 2008). In the 
adipose tissue JNK1 regulates the expression of IL-6 that seems to impair insulin signaling in 
the liver but not in adipose tissue or muscle (Sabio, Das et al. 2008). In the muscle, JNK1 
seems to play a role in the suppression of insulin signaling (Sabio, Kennedy et al.). The liver 
specific knockout of JNK1 revealed a positive role for JNK1 in insulin signaling, (Das, Sabio 
et al. 2009) or had no phenotype (Wunderlich et al, unpublished data).  
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4.2.4       Inhibition of JNK can only partially restore insulin signaling in p38α deficient 
               hepatocytes 
 
Due to the hyperactivation of JNK in p38α deficient livers, primary hepatocytes were treated 
with a JNK inhibitor, before insulin stimulation, in an attempt to rescue the impaired signaling. 
Despite clearly reduced JNK activation as seen from the reduced c-Jun phosphorylation after 
inhibitor application, insulin signaling could only be restored to a very mild degree (Fig. 20). 
This supports studies claiming that JNK signaling in hepatocytes may not have a strong 
effect on insulin signaling (Das, Sabio et al. 2009) (Wunderlich et al, unpublished data).. 
 
4.2.5       Increased phosphorylation of Ser307 in p38α deficient hepatocytes 
 
The negative regulatory phosphorylation of the IRS1 has been discussed as a major 
mechanism by which inflammatory kinases inhibit insulin signaling. Accumulating evidence 
shows that JNK and other kinases can promote increased IRS1 phosphorylation at Ser 307 
leading to an impairment of insulin signaling (Aguirre, Uchida et al. 2000; Aguirre, Werner et 
al. 2002; Hirosumi, Tuncman et al. 2002; Lee, Giraud et al. 2003). Recently, controversy has 
been raised by several in vivo studies investigating the role of serine residues on IRS1 in the 
transduction of the insulin signal. On the one hand germ-line mutational analysis in mice 
demonstrates that Ser-307 on IRS1 is not essential for insulin resistance, in vivo (Copps, 
Hancer et al.). On the other hand the mutation of three serine residues of the IRS1 in the 
muscle protected mice from the development of diet induced obesity and insulin resistance 
(Morino, Neschen et al. 2008). 
Independent from this controversy, the phosphorylation status of IRS1 at serine 307 was 
examined. Indeed, as shown in Fig. 21 p38α deficient hepatocytes show increased 
phosphorylation of IRS1 at serine 307. A JNK inhibitor was applied to decrease the 
phosphorylation of IRS1 at serine 307, in p38α deficient hepatocytes. Similar to insulin 
receptor signaling, the application of the JNK inhibitor failed to reduce the phosphorylation of 
IRS1 at serine 307, suggesting that other kinases might be involved in this 
hyperphosphorylation. It also has to be considered that the insulin receptor substate 1 and 2 
have a high degree of redundancy (Kubota, Kubota et al. 2008). Thus, the status of the IRS2 
protein, which was not addressed in this study, remains to be investigated. Furthermore, IRS 
independent effects that impair insulin mediated signaling cannot be ruled out and have to be 
investigated in further detail (Hoehn, Hohnen-Behrens et al. 2008). 
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Finally, the activation of the upstream kinases MKK4, ASK1 and TAK1 was tested. All these 
upstream kinases seem to be hyperactivated in p38α deficient hepatocytes (Fig. 21). This 
suggests that a whole set of kinases is hyperactivated in p38α deficient hepatocytes, which 
could orchestrate the increased phosphorylation of IRS1 at serine 307. In this case, it might 
not be JNK alone leading to the impairment of insulin signaling but a whole set of kinases, 
including TAK1, which is very proximal to the TNF receptor. TAK1, MKK4 and ASK1 have 
not been implicated in the development of insulin resistance thus far. Future studies are 
required to show if indeed one of these kinases can dampen insulin mediated signals in p38α 
deficient hepatocytes.  
In conclusion, deletion of the p38α MAPK in liver parenchymal cells results in decreased glucose 
tolerance and increased insulin resistance in obese mice. p38α deficient livers and isolated 
primary hepatocytes show decreased insulin signaling. Liver lipids remain unaffected, ruling out a 
possible accumulation of lipid intermediates that could negatively regulate insulin signaling. 
Moreover, an elevated expression of the inflammatory cytokines TNF, IL-1β or IL-6 in the liver, 
was not detected. Increased activation of JNK and its upstream kinases MKK4, TAK1 and ASK1 
is likely to be responsible for causing increased insulin resistance in p38α-deficient hepatocytes, 
through an unknown mechanism. Therefore, in obese mice, liver p38α may have an important 
function regulating glucose homeostasis, by controlling the activity of kinases that might be 
responsible for the negative regulation of insulin signaling. These results also strongly argue 
against the administration of JNK inhibitors to treat chronic inflammatory states in obese 
individuals (Kumar, Boehm et al. 2003). 
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5. Perspectives 
 
In this study liver p38α was shown to have very important functions in chronic and acute 
inflammatory conditions. In acute inflammatory states, induced by LPS injection p38α, 
collaborates with IKK2 to protect the liver from LPS/TNF-induced failure by controlling JNK 
activation. In chronic inflammatory states, caused by diet induced obesity p38α ensures a 
better glucose homeostasis by controlling kinases in the JNK signaling pathway. 
 
In both studies, the molecular basis for the hyperactivation of these kinases could not be 
identified so far. Future studies are required to show how p38α maintains the balance 
between the kinases, keeping the liver in homeostasis. Here, evidence points to a defect 
which seems to be very proximal to the TNF receptor itself since MAP3Ks like ASK1 and 
especially TAK1 are hyperactivated. This could be caused by defective scaffolding or the 
lack of a negative regulatory process at the receptor complex itself, like a constitutive 
degradation of TRAF molecules allowing a constant signal to evolve. Both possibilities can 
be explored by biochemical methods like immunoblotting or co-immunoprecipitation. Also the 
involvement of phosphatases cannot be ruled out at this stage. To this end, a reliable 
phosphatase assay should be established to test the activity of candidate phosphatases.  
 
The LPS model of acute liver inflammation leaves the question whether other anti-apoptotic 
molecules are involved in preventing LPS/TNF induced apoptosis. Since the partial inhibition 
of NF-κB sensitizes livers to LPS/TNF induced toxicity, anti apoptotic NF-κB target genes 
including members of the IAP family are likely to play a role. 
 
In the diet induced obesity model, clamp studies should be performed to identify increased 
hepatic glucose production as the cause for decreased glucose tolerance and insulin 
sensitivity in the liver.  
 
Furthermore, the ability of the hyperactivated kinases TAK1, ASK1 and MKK4 to impair 
insulin mediated signaling has to be determined in animal studies. Also, since the defect in 
signaling is so proximal to the TNF receptor the question for the liver specific role of the 
TNFR1 in diet induced obesity and insulin resistance rises and should be addressed in a 
separate conditional mouse model. 
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